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Background: Medications can prevent stroke but are not used optimally. The overarching 
aim of this thesis was to study medication use in patients with previous ischemic stroke or 
transient ischemic attack (TIA) and in all patients with atrial fibrillation. Socioeconomic and 
demographic factors such as sex, education, and income have been associated with 
differences in medication use after stroke. Understanding these associations better may help 
in understanding reasons for suboptimal medication use. In the chronic setting, patients with a 
previous stroke are followed in primary care in Sweden. Primary care is thus an important 
target for improving medication use. All patient visits in primary care require that a diagnosis 
is recorded by the doctor in the patient’s electronic medical record. This “recording” of 
diagnoses has been hypothesized as a potential quality indicator, but the utility has not yet 
been proven. Also, the association between diagnosis recording and medication use has not 
been studied. Audit & feedback is a commonly used approach to achieve changes in behavior 
in healthcare personnel. Changing the prescribing and motivating behavior of primary care 
doctors vis-à-vis stroke/TIA and atrial fibrillation patients could potentially increase 
medication use.     
Methods: All the studies in this thesis were registry based and have included patients ≥18 
years of age from Region Stockholm. The outcome of all studies has been medication use. By 
using the Swedish National Prescribed Drug Register (NPDR), we were able to study 
medication dispensation to patients as a marker of medication use. Study I used cross-linked 
data from the VAL database (see below), NPDR, and Statistics Sweden. Studies II-IV used 
data from the local healthcare administrative database for Region Stockholm, the VAL 
database. Data in VAL is identical to that found in the National Patient Register (NPR) and 
since 2010 also the NPDR. In study I we explored the association between medication use 
and socioeconomic and demographic factors 9-12 months after ischemic stroke/TIA. Study II 
explored the association between diagnosis recording in primary care and medication use for 
the diagnoses stroke/TIA and acute coronary syndrome. Studies III and IV tested if an audit 
& feedback intervention in primary care could improve medication use and diagnosis 
recording in patients with ischemic stroke/TIA (III) or atrial fibrillation (IV).  
Results/conclusions: Use of recommended preventive medications in Region Stockholm has 
increased over time in both patients with prior ischemic stroke/TIA and patients with atrial 
fibrillation. Although statin use has increased, statins are still the secondary preventive 
medication class which is used the least after ischemic stroke/TIA. The sex gap in statin use 
after ischemic stroke/TIA has persisted over time and future interventions should target 
improving statin use particularly in women. High income was associated with being 
dispensed more statins, anticoagulants, and antiplatelets 9-12 months after ischemic 
stroke/TIA. Having a diagnosis recorded in primary care was associated with greater use of 
antithrombotics and statins in ischemic stroke/TIA, and acute coronary syndrome. Also, 
recorded atrial fibrillation patients used more anticoagulants. An audit and feedback 
intervention did not improve the utilization of preventive stroke medications in primary care. 
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Taking medications regularly is an important part of preventing cardiovascular disease such 
as stroke or heart attacks. Life style factors such as smoking cessation, diet, and physical 
exercise may be just as important as medications. However, life style changes are difficult 
and medications are not always used optimally. Improving medication use and thereby 
preventing stroke is the focus of my PhD project. Why do we need to study the subject of 
medication use? The doctor prescribes you something for your condition and you take the 
medicine as ordered right? Just pop open the bottle and swallow the tablet with some water - 
easy! The reality is much more complicated. Taking the appropriate medication in the correct 
dose, at the correct time, and regularly as intended is a challenge. Why? There are a multitude 
of reasons. First, the doctor must identify that you need a certain medicine in the first place 
and then prescribe it. But once the doctor has given you the prescription, taking just one 
medicine every day seems simple enough right? How easy is it though when you have five 
medicines to take? Or ten? Moreover, some medicines may need to be taken in the morning, 
and some in the evening. Patients seldom have symptoms of high cholesterol or high blood 
pressure, and sometimes atrial fibrillation is asymptomatic. Furthermore, with medicines that 
treat high blood pressure or high cholesterol or anticoagulants, you don’t really see any direct 
effect. They are taken to prevent something from happening in the future. This can be 
contrasted against for instance pain medications which give quick relief of symptoms. In this 
case a patient would be more likely to remember to take them. For patients that have had a 
stroke or a heart attack one of our most important roles as doctors is to prevent recurrence of 
disease. Taking medications regularly can reduce a patient’s risk of having a new event. This 
is why medication use interests me greatly and why I feel my project is of great importance. 
Because my studies I-IV have many topics, my thesis covers a wide range of subjects. Statins 
are the secondary preventive medication class which is used the least. Also, in registry studies 
it is important to know if the diagnoses in the registries are correct, so that you can be certain 
of studying the correct patients. For these reasons, focus in this thesis will be on statins and 




1.1 STROKE – EPIDEMIOLOGY AND PREVENTION 
1.1.1 Epidemiology of ischemic stroke and TIA 
Ischemic stroke and transient ischemic attacks (TIA) cause significant morbidity and 
mortality in Sweden as well as worldwide1,2. According to the Swedish National Stroke 
Register (RiksStroke) there were 8 430 TIA and 21 090 cases of stroke in 2019, of which 
86% were ischemic2. The 90-day mortality in stroke patients in RiksStroke was 16% in 
20192. Even though symptoms from a TIA by definition resolve spontaneously within 24h, 
patients are at an increased risk of ischemic stroke the following weeks and months3.  
1.1.2 Socioeconomic- and sex differences in stroke 
1.1.2.1 Socioeconomic differences 
A low socioeconomic status is associated with worse outcomes in stroke4. There are different 
measures of socioeconomic status, but income and education are two commonly used 
measures4. People with lower socioeconomic status have a higher risk of having a stroke4. 
Furthermore, stroke patients with lower socioeconomic status have higher short term 
mortality and functional outcome; and have more severe strokes4.  
1.1.2.2 Sex differences 
There are also sex differences in stroke. Women are on average 4 years older than men when 
they have their first stroke5. A consequence of this age difference is that women who have a 
stroke are more likely to be living alone6, potentially leading to delayed detection and 
treatment. Also, women may be more likely than men to experience atypical symptoms of 
stroke, such as generalized weakness or altered mental status6,7. On a group level women 
have different pre-stroke characteristics than men with more atrial fibrillation and 
hypertension, but less ischemic heart disease8. Women have a worse functional outcome than 
men one year after stroke, and also lower 1-year survival9. However, a Swedish study found 
that when adjusting for multiple confounders, the odds of survival were actually higher in 
women9. Finally, women may be prescribed less secondary preventive medication, 
particularly statins2,10. 
1.1.3 Prevention of ischemic stroke/TIA 
Many aspects of stroke prevention need to be improved11,12. Prevention can be divided into 
primary prevention – preventing the first stroke – and secondary prevention – preventing a 
recurrence of disease. There are several potential targets for primary prevention in ischemic 
stroke 13. Ten modifiable risk factors for ischemic stroke have been identified and may confer 
up to 90% of the population risk of having a first stroke13. The risk factors include diabetes, 
smoking, hypertension, unhealthy diet, high waist-to-hip ratio, high alcohol use, atrial 
fibrillation, physical inactivity, and dyslipidemia13. Once a stroke has occurred, secondary 
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prevention becomes important. This includes the prompt identification and treatment of 
symptomatic carotid stenosis; diagnosing atrial fibrillation; pharmacological treatment; and 
lifestyle changes14,15. The pharmacological component of secondary prevention, i.e. drug 
treatment, in ischemic stroke/TIA is far from optimal16.   
1.1.3.1 Pharmacological secondary prevention of ischemic stroke/TIA 
Pharmacological secondary prevention after ischemic stroke/TIA consists of treatment with 
several different drug classes, which in most cases are meant to be taken daily and 
indefinitely14,15.  Statins are recommended to all patients presumed to have stroke of 
atherosclerotic origin14,15. National Swedish guidelines have for several years recommended 
that >75% of patients with ischemic stroke should be treated with statins at 12-18 months 
after their stroke17. In 2018 the target levels were increased to >80%18. Furthermore, local 
guidelines in Stockholm have recommended statins for all ischemic stroke/TIA for many 
years19, a standpoint which now has support in the litterature20. In addition to statins, patients 
with ischemic stroke/TIA are recommended antiplatelet drugs such as acetylsalicylic acid or 
clopidogrel. If the patient is diagnosed with atrial fibrillation, oral anticoagulants replace 
antiplatelets as the drugs of choice. Finally, antihypertensive drugs which lower blood 
pressure are recommended. European guidelines14 suggest treating all patients irrespective of 
blood pressure level whereas American guidelines15 only recommend treatment if the patient 
is hypertensive, with a goal of 140/90 mmHg or lower. 
1.1.3.2 Atrial fibrillation 
Diagnosing and treating atrial fibrillation adequately is an important part of stroke 
prevention14,21. Atrial fibrillation is prevalent in approximately 3% of the Swedish adult 
population22 and confers and increased risk of ischemic stroke/TIA21. In 2019, 20% of 
patients with ischemic stroke in Sweden under the age of 80 and 43% over 80 had atrial 
fibrillation2. Atrial fibrillation is slightly more common in men (57% of all patients). This sex 
difference persists across all age groups22. The median age for patients with atrial fibrillation 
in Sweden is 74, and patients frequently have hypertension, diabetes, and other 
cardiovascular comorbidity22,23.  
The European Society of Cardiology (ESC) atrial fibrillation guidelines recommend using the 
CHA2DS2VASc scoring system to identify patients with atrial fibrillation at increased risk for 
ischemic stroke/TIA21. The CHA2DS2VASc score threshold for treatment with anticoagulants 
has changed somewhat over the years. The 2010 ESC guidelines recommended 
anticoagulants in all patients with CHA2DS2VASc of ≥2 regardless of sex24. Since, 2012 
treatment with anticoagulants is recommended by the ESC in men with a CHA2DS2VASc 
score of ≥2 and women with CHA2DS2VASc of ≥321,25. According to current ESC guidelines, 
treatment with anticoagulants can be considered if the CHA2DS2VASc score is ≥1 in men and 
≥2 in women21. Regardless of how guidelines have changed over the years, a diagnosis of 
ischemic stroke/TIA concurrently with atrial fibrillation has always been an indication for 
treatment with anticoagulants21,24-26.  
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1.2 THE STUDY OF MEDICATION USE 
1.2.1 Clarifying the terminology in medication use research 
1.2.1.1 Adherence, compliance, and concordance 
Understanding the field of medication use research is complicated by the existence of many 
similar terms that have often been used interchangeably27. The term “compliance” has 
historically been popular in medication use research27. Compliance in medication use 
essentially means the extent to which a patient is taking their prescribed/recommended 
medication28. Compliance may denote a hierarchy in the patient-doctor relationship where the 
patient’s role is to simply follow orders27,28. It also suggests that non-compliance is the fault 
of the patient28. The use of the term “adherence” has increased in later years27. Adherence 
highlights that the recommended treatment is a result of a patient-doctor interaction and not 
just a decision on the part of the doctor28,29.  Thus adherence means the extent to which a 
patient follows agreed upon recommendations/prescriptions28. Accordingly, non-adherence is 
seen as a joint patient-doctor responsibility and does not assign blame only to the patient28,29. 
Concordance, while sometimes being used synonymously with compliance/adherence, does 
not mean the same thing28,30. Concordance is a somewhat complicated term that focuses on 
patients’ views and beliefs and implies a negotiation/discussion process between patient and 
doctor28,29,30. Furthermore, concordance is more difficult to measure than adherence or 
compliance30. A full discussion of the term concordance is beyond the scope of this thesis.  
In conclusion, while the terms adherence and compliance are similar, I believe adherence to 
be the better term since it denotes a more including patient-doctor relationship. Thus I will 
use term adherence in this thesis.  
1.2.1.2 Components of medication adherence 
Medication adherence can be divided into three components – initiation, implementation, and 
discontinuation27. Initiation is when a patient takes the first dose of a prescribed medication27. 
Discontinuation is immediately after the patient has taken the last dose27. Implementation is 
the time period between initiation and discontinuation27. The implementation is the time 
period where it can be determined to what degree the patient follows the agreed upon dosing 
plan as intended27. Questions that can be answered by studying the implementation period 
include – Are the correct number of doses taken each day? At the correct time? Are doses 
missed? Furthermore, primary non-adherence denotes a patient not picking up the first 
prescription of the medication10.  
1.2.1.3 Persistence 
Persistence means the time period from initiation to discontinuation27. If a patient is 
persistent to treatment it means that they continue to take the prescribed medication, having 
initiated treatment at some point. If patients are asked if they are still taking a medicine 
twelve months after starting treatment and they answer “yes” then they may be considered 
persistent. However, we have no idea how adherent they are. They could potentially only 
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have picked up two 90-day prescriptions during the twelve months in which case they would 
only have had pills lasting for half of the 12 months. In this particular situation patients are 
considered to be persistent to treatment, but they are most definitely non-adherent. 
1.2.2 Why is the study of medication use important? 
Persistence to recommended mediations declines with time after ischemic stroke leading to 
potentially worse outcomes for patients16. The positive effects of good adherence/persistence 
to preventive medications on the prevention of cardiovascular disease have been reported in 
several publications31-37. 
1.2.3 How can medication use be studied? 
Medication use can be studied using many different methods, all of which have advantages 
and disadvantages38. Methods can be subjective or objective, with the most common 
subjective being self-reported medication use or doctor-reported use38. Furthermore, methods 
can also be divided into direct or indirect38. Direct methods study the drug content in bodily 
fluids, like blood or urine, and are objective. Indirect methods can be both subjective and 
objective. The subjective, indirect methods include patient interviews, questionnaires, and 
scales, like the commonly used Morisky Medication Adherence Scale38. Finally, the 
objective, indirect methods include pill counting; using electronic medication packaging 
devices; and registry/database analysis. A discussion of the strengths and limitations of all the 
above methods is beyond the scope of this thesis. I will focus on the registry/database 
methodology since this is what was used in all the studies in this thesis.   
1.2.4 Why did we choose to use registries/databases in our studies? 
Registries/databases are being used increasingly to study medication use39,40. Using 
registries/databases in medication use research has many advantages. It does not 
inconvenience patients. Also, it has the advantage of being cheap, and enabling the study of 
medication use in large populations over longer periods of time39. Using any of the other of 
the direct or indirect measures in a large population of patients would be enormously resource 
consuming, and often unfeasible.  
1.2.5 An important limitation – dispensation ≠ taking a medication 
Often, registries contain dispensation data41. As can be seen in figure 1, taking a prescription 
medication entails several steps, one of which is picking up the medication from the 
pharmacy – being dispensed. However, being dispensed a medication does not mean that a 
patient takes it in the intended way, or at all. Furthermore, if a registry only contains 
information on dispensation and not prescription, which can be the case41, the mechanisms 
underlying non-adherence/non-persistence can be difficult to ascertain. If a patient has not 
been dispensed a medication it can either be because they have not picked up an existing 




Figure 1. An illustration of the chain involved in patients taking their medication. Images 
downloaded from www.pixabay.com and are free to use commercially.  
1.2.6 Methods for studying medication use in registries/databases 
There are an abundance of specific methods for studying medication use in 
registries/databases38. This section will give a short introduction to some of the more 
commonly used methods, and methods used in the studies in this thesis.  
1.2.6.1 Medication Possession Ratio and Proportion of Days Covered 
Registry dispensation data can be used to approximate adherence by calculating the 
Medication Possession Ratio (MPR) or the Proportion of Days Covered (PDC). These are 
two of the most commonly used methods in adherence research33. They are similar but with 
some small differences42. The MPR summarizes all the daily doses dispensed in a defined 
time period and divides that number of daily doses with the number of days in the time 
period. This has the obvious disadvantage of sometimes overestimating adherence if a patient 
choses to pick up dispensations early. In these cases the MPR can be >100%, which can 
make population studies challenging if the researcher is studying an average of the MPR. The 
PDC can never exceed 100%.  When calculating the PDC, the number of days that are 
covered by dispensed medication in the study period are also calculated. However, since the 
maximum number of days which can be covered in a study period of 60 days is 60 days, the 
maximum PDC is 100%. 
1.2.6.2 Persistence 
Persistence can also be studied in registries. Often, a patient is considered to be persistent to 
treatment if they continuously pick up the medication during a period. In this type of study in 
registries there is generally a “grace period” which is the time allowed from the time one 
dispensation runs out until the next prescription is filled16. Imagine a situation where a 
prescription lasting 100 days is picked up on day 0, and the researchers employ a grace period 
of 30 days. Providing the patient takes a daily dose, the prescription will have run out on day 
100. To be considered to be persistent to treatment the patient needs to pick up a new 
prescription before day 131. If studying persistence after two years, the calculation continues 
for all prescriptions during that period, or until the patient is defined as non-persistent by not 
having picked up medication in the appropriate interval (30 days).  
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1.2.6.3 Number of dispensations in a time period 
This is the method used in the studies in this thesis. One way to study medication use in 
registries/databases is by measuring if a patient picks up a medication a certain number of 
times during a time period of interest43,44. An example can be picking up two dispensations in 
a year in Sweden, where each dispensation generally lasts approximately three months. This 
method can be used to reflect medication use in the chronic setting and shows that a patient is 
taking the medicine and likely intends to continue to take it.  
1.3 THE REGISTRIES/DATABASES USED IN OUR STUDIES 
1.3.1 Cross-linking of registry data in Sweden 
Registry data in Sweden can be linked to other registries thanks to the personal identification 
number which is given to all people who live in Sweden on a permanent basis45. The actual 
linkage is done at the National Board of Health and Welfare (NBHW, Socialstyrelsen). In our 
study I, data from Statistics Sweden was cross-linked to other registry data.  
1.3.2 The National Patient Register 
The Swedish National Patient Register (NPR) records all patient discharge diagnoses in 
hospitals46. It was started in 1964 and has since the start been improved in several ways, 
including identifying patients using the Swedish personal identification number and including 
patient diagnoses from specialized outpatient care46.  
1.3.3 The National Prescribed Drug Register  
The Swedish National Prescribed Drug Register (NPDR) started in July 200541,47. It contains 
medication dispensation data on all prescribed medications which have been dispensed in the 
entire country41,47. Examples of included data in the NPDR are the anatomical therapeutic 
chemical (ATC) code of the dispensed medication, the brand name, strength, package size, 
date of prescription, prescribed amount, and date of dispensation.  
1.3.3.1 A special situation in the NPDR - Multi-dose drug dispensing 
Sweden has a system of multi-drug dose dispensing (MDDD) where patients are dispensed 
ready packed doses of medicine according to their medication list, in sealed plastic bags 
(known commonly as “Apodos”)48. Patients with MDDD often live in nursing homes49. 
Deliveries generally occur every two weeks and every delivery is counted as one dispensation 
in the NPDR50. It should be noted that dispensations in MDDD do not require any active 
action on the patient’s part. Using a specified number of dispensations in a time period to 
define being on-treatment in studies, may not accurately approximate real medication use in 
this group of patients. Sometimes they patients with MDDD are excluded from studies on 
medication use51.      
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1.3.4 Statistics Sweden 
Data on socioeconomy and demography is kept by the government agency Statistics Sweden 
(SCB), which is responsible for national official statistics in Sweden52. Data on income, 
highest level of achieved education, and country of birth can be extracted and linked to other 
registries.   
1.3.5 The VAL database  
The VAL database is the local healthcare administrative database for Stockholm County 
(From 1st January 2019 renamed Region Stockholm) and has been in use since the 1980s53. It 
actually consists of several databases but for the purposes of simplification they will be 
referred to as one database in this thesis54. VAL was created to plan, follow up and evaluate 
quality and economics of health care financed by the region53. A large number of variables 
related to healthcare use are recorded in it53,54. Hospital discharge diagnoses are recorded in 
VAL, and are sent by Region Stockholm to the NPR53. Thus, discharge diagnoses are 
identical in VAL and the NPR. Furthermore, primary care diagnoses are registered in VAL, 
data which is not available on a national level53. Also, since 2010, VAL contains data on 
medication dispensation, which is reported to VAL from the Swedish eHealth Agency54. The 
Swedish eHealth Agency also supplies data for the NPDR47. Thus, dispensation data in VAL 
and the NPDR are identical. However, in study I dispensation data had to be acquired from 
the NPDR since it was not available in VAL at the time54.  
1.4 MEDICATION USE AFTER ISCHEMIC STROKE/TIA  
1.4.1 Initiation of medication and chronic management  
Ischemic stroke, TIA, and atrial fibrillation are conditions for which chronic treatment with 
medication is warranted and this chronic treatment is generally managed by primary care 
doctors in Sweden. As stroke patients are generally treated in hospital when they have their 
event, medication therapy is initiated in hospital in most cases. In Sweden, prescriptions are 
valid for one year from the date they are issued55. Thus, after one year, patients need new 
prescriptions. Follow up routines in Sweden differ somewhat regarding ischemic stroke and 
TIA, but generally patients are not followed up by the hospital after one year. The 
responsibility then falls on primary care. In atrial fibrillation, treatment with anticoagulants 
may be initiated either in hospital or in primary care, but prescriptions in the long term are 
generally handled in primary care. The one exception in Stockholm has been with the advent 
of non-vitamin K antagonist oral anticoagulant (NOAC) treatment where NOAC treatment 
initially was handled by hospitals and specialist outpatient clinics56.  
1.4.2 Medication use after ischemic stroke/TIA is suboptimal  
1.4.2.1 Overall interpretation of the literature 
When going through the literature from more than five years ago (when my PhD project was 
started) it is clear that medication use after ischemic stroke/TIA was suboptimal for all 
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medication classes but better for anti-hypertensives and anti-platelets than for statins and 
anticoagulants. I believe that the most representative data on medication use after ischemic 
stroke/TIA comes from registry/database studies on large, unselected populations using 
dispensation data10,16,57.  
1.4.2.2 Studies on persistence and the limitations of studying only persistence 
Persistence to medical therapy after ischemic stroke/TIA is 56-76% for statins10,16,34,58,59, 74-
95% for antihypertensives10,16,58-60, 45-96%  for antiplatelets10,16,31,58-63, and 32-90% for 
anticoagulants  (in patients with atrial fibrillation)10,16,58-62,64. These studies have only 
included patients who had received a prescription for, or were taking the medication in 
question, on discharge. Thus, simply data on medication persistence cannot be used to 
appreciate the proportion of all patients with previous ischemic stroke/TIA who are treated 
with the medication in question. For example, in a Swedish registry study of 21 077 ischemic 
stroke patients, only 7 275 patients were discharged with a statin prescription16. At two years 
the number of persistent users was 3 556 which gave a persistence of 56%. Another study 
observed a statin persistence of 76% at one year after ischemic stroke/TIA58. Only 1 830 out 
of 2 457 (78%) patients received a prescription at discharge.  
1.4.2.3 Cross-sectional studies evaluating medication use    
 
Other studies evaluating cross sectional medication use in patients with prior ischemic 
stroke/TIA, irrespective of prescription status, have found that 40-57% use statins57,65, 74-
86% antihypertensives57,65, 74-100% use antiplatelets57,65-67, and 13-76% use 
anticoagulants57,65,67,68 (in patients with atrial fibrillation). The study observing 13% use of 
anticoagulants was from in China67, whereas the other two studies observing 54%, 63%, and 
76% were from Sweden57, the Czech Republic65, and Germany68.  
1.4.2.4 Study heterogeneity and limitations        
 
Studies on medication use after ischemic stroke/TIA exhibit methodological, geographical 
and temporal heterogeneity. When performing a systematic literature search, I identified 16 
relevant studies, which relate to medication use after ischemic stroke and TIA. Some studies 
were excluded due to low quality and/or inadequate description of the methodology. 
Methodological limitations were present in many of the 16 studies, particularly those 
reporting high persistence. There were four single center studies34,60,63,64, and these are less 
likely to be generalizable to other contexts since there may be unique characteristics in that 
specific center that are not applicable to other settings. Loss of follow up was an issue in two 
studies. There was loss of follow up of around 10% in one study59. In the other study, centers 
with <80% data collection were excluded, which led to an exclusion or loss of follow up of 
66% of patients originally eligible for analysis62. There were only five out of 16 studies 
which used dispensation data to define persistence or medication use10,16,31,57,63. All the other 
non-registry studies used self-reported medication use at a certain time point after the 
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ischemic stroke/TIA. Self-reporting will likely give a higher persistence than the dispensation 
based approach with grace periods, which is a more strict definition. Also, registry/database 
studies have the advantage of including large, unselected cohorts of patients with prior 
ischemic stroke/TIA. This will limit selection bias which may be present in other studies 
which apply inclusion/exclusion criteria, and experience loss of follow up. There were only 
three studies matching that description, all from Sweden10,16,57. Registry/database studies also 
have the advantage of patients not being affected by them being included in a study. The 
study that observed the highest persistence to antihypertensives (95%) was also a single 
center study and patients were contacted at six and twelve months, which may have affected 
their medication use60. One study reporting persistence of 89% to antiplatelet therapy and 
79% to anticoagulants, was in the context of a clinical trial and may not reflect the real life 
situation61. In the study reporting the highest anticoagulant persistence (90%) only 70% of 
patients with atrial fibrillation and stroke were discharged with an anticoagulant64. Some 
studies may not be generalizable because they are conducted in a very specific context, like 
one Chinese and one Spanish study which selected patients in neurological outpatient 
clinics66,67. Interestingly, the Spanish study is the only one of the 16 identified studies that 
used a direct method for evaluating medication use – 66 patients who received aspirin all 
exhibited thromboxane A2 synthesis inhibition, indicating that all patients were taking 
aspirin66.  
1.5 ANTICOAGULANT USE IN ATRIAL FIBRILLATION IS SUBOPTIMAL  
Medication use in atrial fibrillation has historically been suboptimal, both in Sweden and 
internationally22,23,69,70. There are sex and age differences in treatment with women and the 
elderly using less anticoagulants22,23,70-73. The mechanisms underlying sex differences in 
anticoagulant treatment in atrial fibrillation are not clear. Suggested contributing factors have 
been the possible increased risk of bleeding in women taking warfarin71,74,75. Another 
contributing factor may be the increased prevalence of complicating comorbidities in 
women23, and that women with atrial fibrillation in general are older than men22.   
In addition to patients with a clear indication not being treated with anticoagulants, 
inappropriate treatment has also been a problem. In 2011 in Stockholm, 30% of men and 32% 
of women with CHA2DS2VASc score 2-4 were only treated with aspirin23. For 
CHA2DS2VASc score 5-9 the proportions were 36% for men and 40% for women23. 
Conversely in low risk patients, 24% of men with CHA2DS2VASc 0 used anticoagulants, and 
18% of women with CHA2DS2VASc 123. 
1.6 MECHANISMS OF SUBOPTIMAL MEDICATION USE  
1.6.1 General mechanisms 
Patient non-adherence is multifactorial and complex. Osterberg reviews potential predictors 
of non-adherence in general in an article from 200576. Among potential predictors of non-
adherence in general are psychological problems, asymptomatic disease, inadequate follow-
up, side-effects, lack of belief in benefit, lack of insight into illness, and complexity of 
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treatment76. Physicians are likely implicated in some of these predictors through failure to 
explain benefit or side effects of medications76. Adherence can be classified as unintentional 
– i.e. forgetting – or intentional – i.e. motivational problems, not understanding benefits of 
medications or other beliefs concerning medications77. Data on reasons for suboptimal 
medication use can be acquired in different ways. Sources can be qualitative interview 
studies, questionnaire studies or registry/database studies. Information from qualitative 
interviews has the advantage of giving more detailed reasons for non-adherence whereas 
registry/database studies often only provide an association.  
1.6.2 Mechanisms in stroke patients 
When studying the literature on non-adherence in stroke from qualitative or questionnaire 
studies many of the reasons for non-adherence seem to be intentional. Concerns about 
medication is a recurring theme78-83. These concerns about medication may partially be a fear 
of side-effects. This is worrying since many stroke patients do not know, or understand, the 
possible side-effects of medications after hospital discharge84. A second theme revolves 
around the understanding of different aspects of treatment such as why medications are 
supposed to be taken, potential benefits, and the chronic nature of the disease 58,78,83,85-87. If 
patients are not sure of the benefits of a medicine, it stands to reason that they are more likely 
to discontinue it if they have side-effects. Also, if they do not understand that they have a 
chronic disease which needs life-long treatment, they are probably more likely to stop their 
treatment. Patients in a study set in a low socioeconomic setting in the US stated low trust in 
their doctor and problems communicating with their doctor as reasons for non-adherence 82. 
Patients with a previous stroke often have cognitive symptoms which could theoretically lead 
to forgetting/unintentional non-adherence. However, a meta-analysis on non-adherence to 
medications after stroke found no association with cognitive impairment88. A possible 
explanation is increased support from care-giver and/or home nursing 89.  
Studies reporting associations between different factors and higher or lower medication use 
after stroke are very heterogeneous and thus hard to draw any conclusions from16,31,34,51,58-
61,90-92. 
1.7 IMPROVING MEDICATION USE AFTER STROKE 
1.7.1 Feasible interventions that can improve medication use after stroke in 
large populations are lacking 
One purpose of this thesis was to find ways of improving medication use in a large 
population of patients with previous ischemic stroke/TIA in Region Stockholm. Two 
systematic reviews of interventions aimed at improving the use of medications after stroke 
have not, identified any studies which can be used to improve medication use in large 
populations of stroke patients93,94. The few interventions that may be beneficial have 
limitations, and require considerable resources, which make them hard to introduce on a 
broad scale. Furthermore, few studies have focused on improving long term medication use 
in the primary care setting93,94. 
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1.7.2 Studies with beneficial effects and their limitations 
1.7.2.1 Study characteristics 
Two systematic reviews have included studies evaluating interventions that could improve 
medication use after stroke93,94. One included interventions focusing on medication use 
specifically and identified 17 studies93. The other included interventions aimed at improving 
control of modifiable risk factors after stroke (42 studies), of which medication use was an 
outcome in 21 of the studies94. Only nine out of 38 studies in the two reviews found any 
beneficial effects on medication use93,94. There were many different components of the 
interventions, which varied between studies93. Interventions included educating and 
motivating patients; simplifying medication regimes; home visits; regular telephone follow 
up; and addressing patient concerns and beliefs93,94.  
1.7.2.2 Limitations of the studies showing benefit 
Although nine of the 38 studies found beneficial effects on medication use, there were 
significant limitations95-103. Three of the nine studies did not include a control group96,97,100, 
and another did not adequately randomize95. Five studies had relatively short follow up of 
three months98, six months103 and one year97,101,102, respectively. Although not necessarily a 
limitation, only three of the nine studies were in a community setting95,96,100, and the others 
were initiated in hospital97-99,101-103. Overall, the number of included patients was small with 
seven of nine studies including 20-414 patients95-99,101,103. In the study with 20 patients, most 
patients were adherent to begin with96. Most of the interventions were resource consuming95-
97,99,101,102. For example, in one hospital based study the intervention included contacting 
patients by telephone at 2, 6, 12, and 52 weeks; involvement of primary care physicians; 24 
hour ambulatory blood pressure monitoring; mail send outs with personalized risk factor 
profiles; educational sessions; and in-person follow up97. 
1.8 IMPROVING MEDICATION USE IN ATRIAL FIBRILLATION 
Few interventions have been able to increase the use of anticoagulants in the primary care 
setting. However, a multinational study of approximately 2 000 patients showed that a 
complex educational intervention targeting both doctors and patients increased use of 
anticoagulants104. The increase in proportion of patients using anticoagulants was 68% to 
80% in the intervention group, and 64% to 67% in the control group. Aside from this one 
publication, which was somewhat resource consuming, results from other studies have not 
been convincing105-110. The main focus of these other studies has been some form of decision 
support tool for doctors.  
1.9 AUDIT & FEEDBACK FOR IMPROVING MEDICATION USE 
Audit & feedback was the method used in the intervention in studies III and IV. This section 
will give an introduction to audit & feedback; the rationale for choosing it as the intervention; 
and an overview of previous intervention studies involving audit & feedback. 
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1.9.1.1 Audit & feedback – what is it?  
Audit & feedback is an extensively studied method for changing healthcare provider 
behavior. A Cochrane Collaboration analysis of the effectiveness of audit & feedback from 
2012 included 140 clinical trials, of which 49 had audit and feedback as their sole 
intervention111. In the other 91 trials, audit and feedback was a major component of a more 
complex intervention. “Audit and feedback” consists of a summary of clinical performance 
(“audit”) which is then provided (“feedback”) to the doctor/provider in question. In general 
“audit and feedback” shows positive results for dichotomous outcomes with a median 
adjusted difference of 4.3 % absolute increase111. The results can however be both negative, 
with a 9% decrease of desired behaviour, and positive, with a 70% increase111.  
1.9.1.2 Why did we choose audit & feedback as our intervention? 
As mentioned in section 1.7.1, few interventions have previously targeted improving 
medication use in large populations of stroke patients in the primary care setting. Since audit 
& feedback has the potential for affecting the medication taking behaviour of a large number 
of patients through a proxy (their doctor), we felt that it was a suitable methodology for our 
purposes. Audit & feedback may be a way to change physician behaviour in the area of 
prescribing and thus increase medication use in patients. Physicians choosing not to prescribe 
medication16, or patients discontinuing medication on physician advice58, may be important 
factors in suboptimal medication use in stroke. The process of patients taking their 
medication entails several steps (figure 1). Physicians have an important influence on all 
steps. They prescribe medications and then motivate patients to pick them up, take them, and 
be adherent to therapy. Thus, achieving physician behavioural change can potentially have a 
positive effect on all the steps in patient medication use.  
1.9.1.3 Audit & feedback research in primary care 
Audit & feedback is widely studied in primary care with 60% of the studies (84/140) in the 
Cochrane meta-analysis being in that setting111. Studies using audit & feedback alone or as a 
part of a larger intervention in primary care have targeted a wide variety of areas. Examples 
include, but are not limited to, number of radiographs requested according to guidelines112; 
management of hypertension113-116; number of lab tests ordered117; cancer 118; blood pressure 
screening119; lipid screening/testing119,120; mammography121 or smoking cessation referrals122; 
compliance with diabetes guidelines123; time in therapeutic range for international normalized 
ratio (INR)124; osteoporosis management125; and identification/diagnosis of dementia126. 
1.9.1.4 Audit & feedback prescription research in primary care 
In addition to the above described areas of research, prescription is a widely targeted area 
for audit and feedback interventions in primary care115,127-137. Both a decrease and an 
increase in prescribing behavior could be targeted in the studies, with the decrease often 
concerning antibiotics or benzodiazepines.  
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1.9.1.5 Audit & feedback in coronary heart disease in primary care 
Some studies of audit & feedback have targeted the management of coronary heart disease 
in primary care, most with neutral results138-145. The studies are heterogeneous with regard 
to size, type of complex intervention combined with audit and feedback, and end-points that 
were targeted. Two studies showed positive results on prescribing of antiplatelets141,145, one 
of which also studied statins145, also with a positive outcome. These studies were however 
small, randomizing 28 primary care centers141 and 28 primary care physicians145, 
respectively.       
1.9.1.6 Audit & feedback in stroke in primary care 
No studies of audit & feedback have, to our knowledge, specifically targeted improving 
prescribing or medication use in stroke prevention in primary care. One study has targeted 
improving antiplatelet drug prescription in TIA patients146. Audit and feedback has been used 
in different stroke studies, but it has often been from a hospital perspective147-152. 
1.9.1.7 Audit & feedback in atrial fibrillation 
I performed a literature search on audit & feedback and atrial fibrillation and only identified 
four studies146,153-155. One study is yet to publish results155, and two were in a hospital setting 
and did not include a control group153-154. The fourth study had controls and was in a primary 
care setting146. In this fourth study, audit & feedback was a component of a more complex 
intervention. The intervention did however not show any convincing results on the use of 
antithrombotics in atrial fibrillation patients.    
1.10 RECORDING A DIAGNOSIS FOR GREATER LONG TERM MEDICATION 
USE? 
1.10.1.1 Recording a diagnosis – definition and hypothesis 
Our definition of recording a diagnosis is that patients receive the same or a related diagnosis 
in primary care as they have received upon hospital discharge for a certain condition (study 
II). We hypothesized that recording of a diagnosis would be associated with greater long-term 
medication use in both stroke/TIA, and ischemic heart disease patients.  
1.10.1.2 Rationale for studying diagnosis recording 
Our hypothesis was that recording a diagnosis could be a quality indicator for adequate care 
of patients with chronic conditions and may be important in overall quality improvement. 
There is a great interest in developing quality indicators for improving the quality of care, 
Sweden already uses quality indicators to compare care between regions and the United 
Kingdom has used primary care quality indicators for many years156-158.  
In 2016, the organization Sweden’s Municipalities and Regions (Sveriges Kommuner och 
Regioner), launched a service called Quality in Primary Care (“PrimärvårdsKvalitet”)159. This 
service is a national system for quality indicators with automatic data extraction from 
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parameters registered in the electronic medical record (EMR). In 2020, 80% of primary care 
centers in Sweden had access to quality indicator data on their patients. Important to note is 
that “Quality in Primary Care” is based on diagnoses recorded in each primary care center. 
Thus, each center will only attain quality data from patients with diagnoses, but not those 
without. This raises an important point of why diagnosis recording may be important. A first 
step in quality improvement of specific chronic diseases, such as ischemic stroke/TIA, is to 
identify the prevalence of the condition. Thereafter an audit of different outcomes of quality 
is possible. In Sweden, regulation limits the use of diagnoses recorded outside of the own 
care giver. Thus, if a large proportion of patients with certain conditions remain unrecorded, 
primary care centers cannot know the true prevalence of chronic conditions in their own 
center. Consequently, quality improvement becomes more difficult.   
Why not study long-term patient medication use directly through dispensation data in the 
NPDR as a quality indicator, instead of diagnosis recording? Medication use data is likely a 
useful quality indicator. Our notion was however that recorded patients using more 
preventive medication could be a surrogate marker for better overall care of the condition in 
question. There are many aspects of chronic stroke care which require the attention of the 
physician. These include, but are not limited to, identifying and treating secondary conditions 
such as incontinence, shoulder pain, central post-stroke pain, depression, and osteoporosis160. 
Other important aspects of chronic stroke care are fall prevention; assessment of cognition 
and memory; and assessment of swallowing160. However, many of these conditions and 
assessments are however difficult to measure compared to medication use. Thus, we wanted 
to perform an initial proof of concept study to see if diagnosis recording could be associated 
with patient outcomes. In study II this patient outcome was the use of recommended 
secondary preventive medication in patients with previous stroke/TIA or acute coronary 
syndrome.  In study III and IV we tested if an audit & feedback intervention could improve 
diagnosis recording.  
1.11 SETTING 
In all the studies we have selected the patients from Region Stockholm. It is an urban region 
of approximately 2.4 million people161. There are six hospitals in the region with emergency 
departments (a seventh, Karolinska University Hospital Solna only admits patients with 











The overall aim of the PhD-project was to study medication use in patients with previous 
ischemic stroke/TIA and in patients with atrial fibrillation. Aims of specific studies were: 
Study I: To identify socioeconomic and demographic factors associated with medication 
utilization 9-12 months after ischemic stroke/TIA.  
Study II: To study if having a diagnosis recorded in primary care was associated with using 
more secondary preventive medication  after stroke/TIA and acute coronary syndrome. 
Study III and IV: To study if an audit & feedback intervention (appendix figure A1) in 
primary care could improve preventive medication use and diagnosis recording in patients 




3 METHODOLOGICAL CONSIDERATIONS 
3.1 STUDY DESIGN AND DATA SOURCES 
 
Table 1. Study design, registries/databases used, and number of patients included in studies I-
IV. NPDR=National prescribed drug register. The VAL database is the local healthcare administrative 
database for Region Stockholm. 
3.2 TIME PERIOD OF THE STUDIES 
The time periods from which patient cohorts were selected for the studies in this thesis is 
shown in figure 2. Study I included ischemic stroke/TIA patients from the 1st January 2006 to 
the 31st of August 2010. Study II included patients with ischemic or hemorrhagic stroke, TIA, 
or acute coronary syndrome (ACS) from the 1st of January 2010 to the 31st of December 
2013. For study III and IV we used two different cohorts of patients with ischemic stroke/TIA 
and/or atrial fibrillation diagnoses. The first cohort included patients from the 1st of July 2009 
to the 30th of June 2014 (index period A), and the second patients from the 1st of January 
2011 to the 31st of December 2015 (index period B).     
 
Figure 2. Time periods from which patients in the cohorts in the studies in this thesis were 
included.  
3.3 OUR MAIN OUTCOME - MEDICATION USE 
3.3.1 Outcomes in studies I-IV 
We defined medication use as a certain number of dispensations in a defined time period. We 
chose one dispensation in a 4 month period in study I, two dispensations in a one year period 
in study II and two dispensations in an 18 month period in study III and IV. 
 Study design Registries/databases Number of patients 
Study I Retrospective cross-
sectional 
VAL, Statistics 
Sweden (SCB), NPDR 19 335 
Study II Prospective cohort VAL 19 072 
Study III Block randomised 
controlled trial VAL 12 766 
Study IV Block randomised 
controlled trial VAL 31 477 
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3.3.2 We wanted to study all patients, not only those with prescriptions 
Why did we choose to study a certain number of dispensations during a time period instead of 
studying adherence or persistence? The main reason for choosing this definition of 
medication use was that we wanted to study all patients (with certain exclusion criteria) with 
previous ischemic stroke/TIA in study III and all patients with atrial fibrillation (with 
CHA2DS2-VASc ≥2) in study IV. As has previously been mentioned in this thesis, the study 
of adherence and persistence (with the exception of primary adherence) generally means 
studying patients who have initiated treatment27,38. We wanted to study all patients in study 
II-IV since they all had indications for treatment according to local guidelines in 
Stockholm19. The rationale for choosing two, rather than one, dispensations during a time 
period in study II-IV was that it may better reflect an intention to continue treatment than just 
one dispensation. It should be noted that, even if all patients have an indication for treatment, 
the goal cannot be to treat 100% of patients after ischemic stroke/TIA with all recommended 
medications. Some patients will develop intolerable side-effects, or may have 
contraindications.  
To summarize, medication use in this thesis describes how medications are dispensed in an 
entire cohort of patients with a certain prior diagnosis, and not just those who have received 
prescriptions. 
3.3.2.1 Terminological considerations in study II 
In study II we used the phrase “Data on dispensation of medications in the entire patient 
cohort was extracted as a marker of adherence”. In retrospect, I believe that it may have 
been better to simply write “as a marker of patients using the medication in question”. Good 
adherence is generally seen as a PDC or MPR ≥80%33. In our patients in study II, two 
dispensations (most often 100 pills per dispensation) in 12 months that was the definition of 
being treated (or adherent), would have covered 55% of days (200/365) in most cases. Thus, 
it is not entirely appropriate to use the term “adherence”. Conversely, it should be noted that 
the term “good medication use” is a broad term which can be used to describe both good 
adherence and/or good persistence.  
3.3.2.2 A special situation – warfarin 
The study of medication use for warfarin is more complicated than for other medication 
classes, if the intention is to study adherence or persistence. For statins, antiplatelets, and 
antihypertensives, the daily dose is often one tablet of each separate medication. In warfarin 
treatment, patients require different doses, and thus a different number of daily tablets to 
achieve the desired INR, often 2.0-3.0162.  
The required daily dose of warfarin for a specific patient, at a specific point in time, is not 
available in the NPDR in Sweden. Thus it is difficult to approximate the number of warfarin 
dispensations which a patient needs during a year. Warfarin in Sweden is available in 100 
tablets per dispensation. Doses required can vary greatly from patient to patient, with a mean 
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of 4.2 mg/day required162. One tablet is 2.5 mg. Thus 100 tablets in one dispensation can be 
estimated to last for approximately 60 days, for a mean daily required dose. It follows that a 
patient taking warfarin will require more than one dispensation in a year. Thus, a patient with 
atrial fibrillation who picks up at least two warfarin dispensations in a specified time period 
in the chronic treatment context, similarly to other medication classes, likely has the intention 
of continuing treatment. This was the basis for our definition of using medication as multiple 
dispensations in a time period. 
3.4 STUDY DESIGN CONSIDERATIONS AND LIMITATIONS 
3.4.1 Socioeconomy, demography, and statin use (study I) 
The aim of study I was to evaluate the impact of socioeconomic and demographic factors on 
the long term use of statins after ischemic stroke/TIA. For this purpose, we selected the time 
period 9-12 months after ischemic stroke/TIA as our dispensation interval.  
3.4.1.1 Choice of time interval 
In retrospect the time interval 9-12 months is somewhat arbitrary. The rationale was that by 
selecting a time period of one year after the initial event, we would capture the long term use 
of statins, when primary care has assumed the prescribing responsibility. The main flaw in 
the choice of the time period 9-12 months is that patients may still have prescriptions 
available from their hospital physician at this point in time as prescriptions can last for, and 
cover, one year. For short term use it may have been more appropriate to study the 
dispensation of a statin in the first three months after discharge and for long term use, a time 
period after one year. For example, medication use could have been defined as two 
dispensations in the time period 12-24 months after ischemic stroke/TIA.  
3.4.1.2 Including prescription data from RiksStroke and more data from the NPDR 
One option could have been to include prescription data at discharge as a variable, by linking 
data to RiksStroke. Also, we could have included more data on dispensations from the 
NPDR, rather than just dispensations in the 9-12 month period after the event. Then we could 
have obtained information on several outcomes - primary non-adherence, adherence, 
persistence, and medication use in all patients - and their association with socioeconomic and 
demographic factors. Such a study design could have yielded further relevant information, 
not available from the results in study I.  
3.4.2 Diagnosis recording and medication use (study II) 
The aim of study II was to investigate the association between diagnosis recording in primary 
care and medication use in stroke, TIA, and ACS.  
3.4.2.1 ICD-code selection for index and recording period 
In all my studies, the patients have been included on the basis of having, or having had, a 
disease. Thus, to be sure that the correct patients have been included in the study, selecting 
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the appropriate international classification of diseases (ICD) codes is of vital importance. 
Ischemic stroke will be used as an example. In the index period in study II, we wanted to be 
sure, with a high level of certainty, that our stroke patients had actually had an ischemic 
stroke. Thus, we limited the number of ICD codes which qualified the patient as having had 
an ischemic stroke. Thus, we selected patients with ICD codes I63.0-9 (see supplementary 
material for study II for all ICD codes). All I63.0-9 ICD codes start with “cerebral infarction” 
and then continue with for example “due to embolism” or “due to thrombosis” and whether 
or not the affected vessel is pre-cerebral or cerebral163.  
In contrast, for the recording period we wanted to have a high degree of sensitivity, i.e. we 
wanted to capture all diagnoses which may have pertained to a previous ischemic stroke. The 
purpose was to ensure that we captured as many ischemic stroke patients as possible who 
received a diagnosis in primary care which could be assumed to be related to their ischemic 
event. This meant that we accepted ICD codes such as I64.9 “Acute cerebrovascular disease 
not specified as hemorrhage or infarction”. The rationale for being permissive with diagnosis 
selection in primary care is that the patterns of diagnosis selection are very variable. Not all 
primary care doctors routinely choose a cerebrovascular disease diagnosis at their patient’s 
yearly check-up. They may simply choose another of the patient’s diagnoses such as 
hypertension or type-two diabetes.  
3.4.2.2 Duration of the recording period 
In study II, we selected patients with a stroke/TIA or ACS diagnosis in a one year period and 
then followed them for a further three years (figure 3). The exposure was if patients received 
a primary care diagnosis equivalent to their initial hospital diagnosis in years two and three 
after their event (recording period, figure 3). We chose a two year interval for the recording 
period to allow for patients who were followed in primary care, but not annually, to be 
recorded.  
 
Figure 3. Definitions of index, recording, and dispensation period in study II. From Dahlgren C, 
Geary L, Hasselstrom J, et al. Recording a diagnosis of stroke, transient ischaemic attack or 
myocardial infarction in primary healthcare and the association with dispensation of secondary 
preventive medication: a registry-based prospective cohort study. BMJ open 2017;7:e015723. 
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3.4.3 Audit and feedback interventions (study III and IV) 
The aim of study III was to evaluate the effect of an audit and feedback intervention in 
primary care on medication use and diagnosis recording in patients with previous ischemic 
stroke or TIA (study III) and atrial fibrillation (study IV).  
3.4.3.1 Block randomization 
Primary care in Stockholm is organized into nine areas of continuous medical education, 
within which most educational initiatives are based. The rationale for not randomizing all 
approximately 200 primary care centers to either intervention or control was that there may 
be a spill-over effect of the intervention between centers in the same educational area. Thus, 
we felt it more prudent to randomize all centers within an entire area of continuous medical 
education to either intervention or control.  
3.4.3.2 Norrtälje centers were excluded 
One area of continuous medical education in Region Stockholm is Norrtälje. We excluded 
primary care centers in Norrtälje, since the organization of healthcare there is different than in 
the rest of the region, with a uniquely integrated model of healthcare and services164,165. A 
publicly owned, privately run company (Tiohundra AB), organizes and runs both the local 
hospital, the primary care centers, and the municipality-run health care services164,165. The 
integrated model means that the mechanisms behind diagnosis recording would have been 
completely different to the rest of the Region, since patients in Norrtälje receive both acute 
and chronic treatment for their stroke/TIA within the same organization.   
3.4.3.3 Who to target with the intervention – doctors directly or center directors? 
We sent the quality reports (intervention) to the primary care center directors in the 
intervention centers. An alternative could have been to send the reports personally to 
individual doctors in all intervention centers. We wanted to use an existing framework where 
the hope was that the directors would use and disseminate the reports internally, using them 
for quality improvement, internal education etc. Our concern was that doctors in primary care 
receive a wide variety of educational material and that our intervention would have become 
simply “another information pamphlet”.  
3.4.3.4 The components of the intervention  
The center directors received the quality reports (see figure A1 in appendix for de-identified 
version), but also a PDF-file with PowerPoint slides which clarified the data in the reports. 
Additionally, the slides contained information on national goals from the National Board of 
Health and Welfare and one slide with a “call to action” regarding stroke prevention. This 
slide contained questions such as “do we know which of our patients have had a stroke?”; 
“are we following up our stroke/TIA patients annually?”; “are we identifying patients with 
atrial fibrillation?”; “what are our patients’ characteristics in our RAVE-reports?”; “can we 
improve our routines?”. Furthermore, an information letter was included, in both the e-mail, 
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and the regular mail. In this letter, directors were encouraged to arrange an internal meeting 
and present the information. Finally, we included a letter, briefly describing how the quality 
reports could be used as the mandatory quality improvement project for the region.   
3.4.3.5 Diagnosis recording was defined differently in study II and study III/IV 
We used a different model to define diagnosis recording in study III and IV compared to 
study II. Instead of an index year (figure 3), we used a diagnosis from the index period and 
then evaluated if patients received a primary care diagnosis during the 18 month dispensation 
period (which was also the recording period in study III/IV). The main differences between 
definitions of diagnosis recording in study II and III/IV are illustrated in figure 4.   
 
Figure 4. Different definitions of periods used for defining diagnosis recording in studies II and 
III/IV. Diagnosis recording was defined as having an initial diagnosis during the index period and then 
being diagnosis recorded in primary care in the subsequent recording period.  
In addition to differences in the definitions of index and recording periods between studies II 
and III/IV, the models used for studying diagnosis recording were different in other respects. 
Patients with multiple diagnoses were not excluded in studies III and IV since we wanted to 
include all patients in the control and intervention centers to reflect the real life situation of 
follow-up. In study II we wanted to be sure that patients were followed in primary care for 
the condition in question as it was a proof of concept study for the association between 
diagnosis recording and medication use. Had we included patients with more hospitalizations 
for a specific condition, we would not have been sure if the hospital or the primary care 
center were responsible for care. Furthermore, if we had included patients with hospital visits 
for several conditions, we could not have been certain of which treatment guidelines applied 
to the patient in question.  
Furthermore, our original data set for study III/IV did not cover a long enough time period to 
allow for the same analysis model as in study II. To determine if the intervention had any 
effect on diagnosis recording using the model from study II, a time period of two years would 
have to elapse to allow for the two year recording period to occur after the intervention 
(figure 5). Our original data set only covered the time period until June 2017. It is possible to 
 
 23 
use the model from study II in the future but it will require an amendment of our data set and 
we currently do not have funding for this.  
 
 
Figure 5. Description of how diagnosis recording could have been analyzed in study III and IV 
according to the model from study II. Our original data set only covered the time period until June 
2017 and thus the model in this figure could not be used.  
3.4.3.6 Which CHA2DS2VASc score when analyzing data in study IV? 
We chose to analyze all patients with CHA2DS2VASc ≥2, in study IV in accordance with 
local treatment guidelines at the time of the study, which were also included in the 
intervention19. In March 2017 local Stockholm guidelines were updated to match ESC 
recommendations166. We performed sensitivity analysis in study IV (unpublished), defining a 
clear treatment indication as CHA2DS2VASc score of ≥2 for men and CHA2DS2VASc of ≥3 
for women in accordance with the ESC recommendation at the time of the study25. We 
wanted to analyze only patients with a clear indication for treatment, which was the rationale 
for not including all atrial fibrillation patients in the analysis of the intervention.  
3.5 COMPARING MEDICATION USE IN STUDY I AND III 
We used different methods to study medication use in study I and III, which should be 
considered when interpreting the data. Study I defined medication use as one dispensation in 
the period 9-12 months after ischemic stroke/TIA and study III as two dispensations in an 18 
month period following a five year index period. While the dispensation period in study I was 
exactly 9-12 months after discharge for all patients, the time period between event and 
dispensation period varied greatly in study III. Since the index period in study III was 2011-
2015, a patient included in study III could for example have had their event on the 1st of 
January 2011 or on the 31st of December 2015. Since the dispensation period was the 1st of 
January 2016 to the 30th of June 2017, this means that patients in study III could have the start 
of their 18-month dispensation period anywhere from one day to five years after their event. 
Finally, in study III we excluded patients living in nursing homes; patients not registered at a 
primary care center; and patients in the excluded primary care centers. These exclusion 
criteria were not applied in study I.  
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3.6 VALIDITY OF THE REGISTRIES USED 
All studies in this thesis have used registries/databases. The patient cohorts in the studies 
were included from registries/databases and the outcomes have also been extracted from 
registries/databases. Thus, it is important to know validity of the registries/databases used.  
3.6.1 Validity of the NPR vs validity of VAL for stroke diagnoses 
Stroke diagnoses in the VAL database have, to my knowledge, not been specifically 
validated. However, since the data on discharge diagnoses are identical in VAL and the 
NPR53, validity studies on stroke diagnoses in the NPR should be applicable to VAL. The 
only caveat being that the NPR is based on national data, whereas the VAL only contains 
data from Region Stockholm. Thus, differences in validity cannot be ruled out, but are likely 
small.  
3.6.2 What does validity mean?  
For a diagnostic test, the tests validity is its ability to measure what you intend it to measure. 
To know if the NPR is valid with regards to stroke diagnoses two questions need to be 
answered – 1) are all patients with stroke captured in the NPR registry?  and 2) does a stroke 
diagnosis in the NPR mean that the patient has actually had a stroke? These questions can be 
answered by studying the sensitivity and the positive predictive value (PPV) for stroke 
diagnoses in the NPR. 
3.6.3 What is the gold standard for stroke incidence in a population? 
To be able to answer the questions posed above (1 and 2), a prerequisite is that we have some 
way of identifying all patients with stroke in a population, a gold standard. The gold standard 
for determining the true number of strokes in a population entails searching for strokes in 
both hospital populations, primary care populations, and cause of death registries167.   
3.6.4 How is sensitivity calculated?  
Sensitivity answers question (1) above – what proportion of strokes are captured in the 
registry? Sensitivity can be calculated as seen in figure 6. Imagine that the gold standard has 
identified 800 “true” strokes (“Stroke (+)”) in a population. 600 of these patients receive a 
discharge diagnosis of stroke in the NPR, 200 do not. Then the sensitivity, i.e. the number of 




Figure 6. Illustration of how the sensitivity of a registry can be calculated relative to a gold 
standard reference (“Stroke (+)”). NPR = national patient register. The sensitivity in the above 
example is 75%.  
3.6.5 How is the positive predictive value calculated? 
In addition to the sensitivity of a registry, the positive predictive value is also of interest. 
While the sensitivity can tell us the proportion of patients with true diagnoses that are missed 
in our registry (25% in the example in figure 6), the PPV answers question (2) – what is the 
likelihood of a registry recorded stroke diagnosis actually being true? Imagine a situation 
where the NPR has diagnosed 700 patients with stroke in a population (figure 7). The gold 
standard tells us that 100 of those patients actually did not have a stroke (“Stroke (-)”) and 
were miss-classified in the NPR. Thus, the PPV is 600/700=0.86=86%.  
 
Figure 7. Illustration of how the positive predictive value (PPV) of a registry can be calculated 
relative to a gold standard reference. NPR = national patient register. The PPV for a stroke 
diagnosis in the NPR in the above example is 86%. 
3.6.6 Swedish studies of stroke incidence 
Several Swedish studies have attempted to ascertain all cases of stroke (both ischemic and 
hemorrhagic) within a specified community168-170 using hospital, primary care, and cause of 
death data. Two of them have only attempted to find all first time events of stroke168,169 with 
one focusing on all strokes170. The “gold standard” community data from these studies has 
been used to evaluate the sensitivity and the PPV of the NPR168-171 (one of the studies169 did 
not specifically intend to evaluate validity against the NPR, but data can still be used for this 
purpose).   
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3.6.7 Sensitivity of the NPR for stroke diagnoses 
The sensitivity of the NPR for detecting all strokes is high, 83-94%170,171, with the reference 
gold standard of true strokes being ascertained thorough community studies of stroke 
incidence. The study which reported 83% sensitivity included patients found in the Causes of 
Death Register (CDR) in the denominator171. If these patients are excluded, then the 
sensitivity of the NPR is 90% rather than 83%. Three studies report the sensitivity of the NPR 
for a first ever stroke to be 84-86%, but these studies have also included dead patients in the 
denominator168,169,171. If the dead patients were to be excluded, sensitivity would be higher. 
Furthermore, in one of the studies, 8% of patients with stroke were evaluated in the 
emergency department and then sent home for outpatient management169. Had they been 
admitted, as may be the practice in other settings, sensitivity would have been 92%.  
3.6.7.1 Why is the sensitivity of the NPR not 100%? 
As described above the sensitivity of the NPR is not 100% for finding all strokes/TIAs that 
actually occur in a defined community population. Most, but not all patients in Sweden are 
treated in-hospital for ischemic stroke/TIA168-170. Patients not treated in hospital for stroke 
will likely be missing from the NPR, which contains hospital discharge diagnoses and 
specialist outpatient clinic diagnoses. Some patients die from their stroke before being 
admitted to hospital. These cases are not found in the NPR, but can sometimes be identified 
in the CDR169,170. Some patients treated in hospital for stroke may not receive a stroke 
diagnosis at discharge168. This is a relatively uncommon occurrence and may be more likely 
in patients treated outside of stroke wards168.  
3.6.8 Positive predictive value of a stroke diagnosis in the NPR 
PPV answers question (2) in the earlier section – is the stroke diagnosis in the registry 
correct? While an older study from 1992 reported a PPV of 69% for a stroke diagnosis in the 
NPR170, more recent studies have described much higher PPVs, 88% for all stroke171 and 94-
97% for a first stroke168,171. The study reporting a PPV of 69% was carried out in 1985-1988, 
when radiological methods for detecting stroke and identifying potential differential 
diagnoses were not as widely available. This may partly explain the higher PPV in more 
recent studies.  
3.6.8.1 Why is the PPV of the NPR not 100%? 
Why are some stroke diagnoses in the NPR wrong? Patients diagnosed with stroke in the 
NPR may have had other diagnoses than stroke such as epilepsy or an anoxic brain injury168; 
received a stroke diagnosis despite diffuse symptoms (vertigo, confusion) and the absence of 
focal neurological deficit170; may have received an incorrect acute stroke diagnosis despite 
only having sequelae after a previous stroke170,172; have been miss-classified as TIA170; and 
finally may have had a traumatic brain injury and not a stroke172.  
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3.6.9 Other sources of validation – RiksStroke 
The national quality registry for stroke, the Swedish Stroke Register, “RiksStroke”173,174, can 
be used to estimate the PPV of stroke diagnoses in the NPR. This can be done since 
RiksStroke annually registers the completeness of data with regards to stroke and TIA 
diagnoses172. A lot of effort is put towards only including patients with actual stroke in 
RiksStroke. Designated staff in stroke units check for the appropriateness of patient inclusion. 
This means that a stroke diagnosis in RiksStroke is very likely to be a true stroke diagnosis. 
To put it another way - the PPV of a stroke diagnosis is likely to be higher in RiksStroke than 
in the NPR. Participation in RiksStroke is voluntary, but non-participation is extremely rare.  
3.6.9.1 Completeness of stroke diagnoses in RiksStroke 
RiksStroke is compared annually to the NPR with regards to completeness. This means 
dividing the number of patients in RiksStroke with a first ever stroke by the total number of 
patients in the NPR with a first ever stroke diagnosis. The rationale for selecting the first ever 
diagnosis when evaluating completeness is that differentiating recurrent stroke vs stroke 
sequelae can be difficult. The completeness has been high, around 90%, for many years172,175. 
3.6.9.2 Relating the completeness of RiksStroke data to the validity of the NPR 
A stroke diagnosis in RiksStroke has a high PPV, i.e. is likely to be a true stroke. Thus, the 
fact that around 90% of first time stroke diagnoses in the NPR are also found in RiksStroke, 
means that the PPV of a stroke diagnosis in the NPR is also likely to be high.  
3.6.10 Validity of ischemic stroke and TIA diagnoses specifically in the NPR 
3.6.10.1 Ischemic stroke 
Studies on the validity of the NPR have focused on stroke diagnoses, not further specified168-
171. Thus, all types of stroke are included in these studies, both ischemic and hemorrhagic. 
Given that the large proportion of stroke, around 85%2, is ischemic, validity studies on all 
stroke should be, in large part, applicable to ischemic stroke as well. Personal communication 
with the RiksStroke representatives has also revealed that unpublished data supports the high 
PPV of ischemic stroke diagnoses in the RiksStroke registry.  
3.6.10.2 TIA  
The validity of TIA diagnoses in the NPR has, to my knowledge, not been studied. The TIA 
diagnoses in the RiksStroke registry have however been validated. A sample of 180 TIA 
patients were extracted and the patient journals were reviewed by two assessors, one 
neurologist and one physician with a specialist interest in neurology176. In 93% of cases, at 
least one of the assessors found a TIA diagnosis to be likely or possible. In 77% of cases both 
assessors agreed that a TIA diagnosis was likely or possible. The completeness (also 
compared to the NPR) of a first time TIA diagnosis in RiksStroke is 85%, but has only been 
recorded since 2018172.  
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TIA is a more difficult diagnosis than stroke in the sense that sometimes a diagnosis is 
recorded based solely on patient history, with no objective findings on physical exam or 
radiology. This fact, together with the completeness being 85%172 and the aforementioned 
validation study176, gives to reason that the PPV of a TIA diagnosis in the NPR is lower than 
for stroke, but may still be relatively high.  
3.6.11 Validity of the NPR regarding atrial fibrillation diagnoses 
While the PPV of an atrial fibrillation diagnosis in the NPR is likely high, with one study 
reporting 81%177 and another 97%178, the sensitivity is probably lower177.  In the second 
study, 97% was the combined PPV for the NPR and the CDR178. The reference gold standard 
in the studies was electrocardiogram (ECG) documented atrial fibrillation177,178. The first 
study, which reported both PPV (81%) and sensitivity of atrial fibrillation diagnoses, 
included 336 patients with ischemic stroke, and 336 age- and sex matched controls without 
stroke177. In total the sensitivity of an atrial fibrillation in the NPR was around 80% in this 
cohort of 672 patients177. For stroke patients (n=336), sensitivity was 82%, and 76% for the 
control group (n=336)177. Thus around 20% of atrial fibrillation diagnoses may be missed if 
only using the NPR as a source. The VAL database has the advantage of also containing 
primary care diagnoses. Since some patients may be managed in primary care and only 
receive their atrial fibrillation diagnosis there, combining the NPR, with hospital diagnoses, 
and primary care data (as in study III and IV) will give a higher sensitivity than the NPR 
alone179.  
3.6.12 Definition of the CHA2DS2VASc score   
Diagnoses from both the NPR and primary care (from VAL) were used to create the 
CHA2DS2VASc variable in study IV. We have used somewhat different definitions of the 
variables included in the CHA2DS2VASc score than some other authors23,44. This will lead to 
a lower prevalence of some of the CHA2DS2VASc variables in our atrial fibrillation cohort in 
study IV compared to some other studies23,44. However, the different definitions of the 
variables in the CHA2DS2VASc score will likely have affected intervention and control 
centers similarly thanks to randomization, and thus will not have affected the neutral results 
of the intervention. 
3.6.12.1 Lower prevalence of vascular disease 
The validity of myocardial infarction diagnoses in the NPR is high46. However, in our study, 
our definition of the “vascular disease” variable in CHA2DS2VASc has led to us reporting a 
lower prevalence of vascular disease than some other studies23,44. The vascular disease 
variable in our CHA2DS2VASc score was defined as any previous ACS or peripheral 
vascular disease diagnosis during a five year period. We may have found more patients if we 
had selected a longer time period, e.g. ten years. Also, we only included unstable angina 
pectoris (ICD I20.0), but not the other chronic forms of angina. Furthermore, the I70 
diagnosis code (different versions of peripheral atherosclerosis) was not included in our 
definition of peripheral vascular disease. Taken together, these definitions led to 9% of the 
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patients our cohort of atrial fibrillation patients 2011-2015 having vascular disease 
(unpublished results). These 9% of patients have a high likelihood of having true vascular 
disease. However, when comparing to contemporary publications, it is obvious that we have 
not included all patients with true vascular disease. These contemporary publications from 
Region Stockholm reported a vascular disease prevalence of 24% and 25%, respectively23,44.   
3.6.12.2 Lower prevalence of diabetes and ischemic stroke/TIA 
We used the dispensation of any antidiabetic medication during a 5 year period to define the 
presence of diabetes mellitus. This will likely capture patients with clinically relevant 
diabetes mellitus, but will give a marginally lower prevalence than when diabetes diagnoses 
are used to define the presence of disease23,44. The high validity of stroke diagnoses in the 
NPR has been previously discussed in this thesis. There are two reasons for the lower 
prevalence in our study compared to other studies23,44. We only included ischemic stroke and 
TIA diagnoses from the NPR, and used the ICD codes I63; G45.0-1; G45.3; and G45.8-9. 
This is a more strict ICD-code definition of ischemic stroke/TIA than other studies, which 
often include more unspecific diagnoses such as I64 and I69.4, and diagnoses from primary 
care23,44. Also, we did not include diagnosis codes for systemic embolization.   
3.6.12.3 Heart failure  
Two studies validating heart failure diagnoses in the NPR have shown a relatively high PPV 
180,181, meaning that patients with a heart failure diagnosis likely have heart failure. Both 
studies used ESC guidelines as the gold standard180,181. A thorough review of medical records 
and collection of relevant information including, but not limited to, echocardiography, x-ray, 
and ECG results was performed in both studies180,181. A PPV of 82% was reported in a study 
from 2005180. In patients where an echocardiography was performed, PPV was 88%180. 
However, while the PPV was 95% for a primary diagnosis of heart failure, the PPV dropped 
considerably if the diagnosis was in position 3-6 (63%)180. This study has the obvious draw-
back of including only men180. A more recent Swedish study included a random sample 
(n=965) of all patients discharged or deceased with a heart failure diagnosis from 2000 to 
2012 in a large hospital in the west of Sweden181. In this sample, 62% of heart failure 
diagnoses were classified as definite, and 32% as probable. When only studying patients with 
a heart failure diagnosis 2009-2012, the proportion of definite cases increased to 83%181. 
Thus, in that region, the PPV of heart failure diagnoses in the NPR has increased with time.  
Like some other authors23,44, we defined heart failure as having a diagnosis in the NPR or 
primary care (from VAL). Thus, we have likely captured more heart failure diagnoses than if 
we had only used the NPR. The prevalence of a heart failure diagnosis in patients with an 
atrial fibrillation diagnosis in 2011-15 was 28% in study IV (unpublished results), which is 
slightly lower than some similar studies23,44. These small differences are likely explained by 
different exclusion criteria and that we did not include right heart failure in our definition 




Our study had the advantage of including primary care diagnoses for the variable 
hypertension. This is relevant since a large proportion of hypertension diagnoses are only 
registered in primary care53. The prevalence of hypertension in our cohort from study IV was 
slightly higher than that of other studies23,44, likely because of differing exclusion criteria. 
3.7 STATISTICAL METHODS 
3.7.1 Considerations when choosing a statistical test  
The choice of statistical method, for both descriptive and inferential statistics, depends on the 
type of variable - categorical or numerical - and which type of scale the variable is measured 
on – nominal, ordinal, or continuous (interval/ratio). The variable type is, for the sake of 
simplification, often referred to by type of scale it is measured on. Categorical variables can 
be measured on a nominal or an ordinal scale. Variables where the values have no inherent 
rank are measured on a nominal scale. Examples are sex, country of birth, and hair color. If 
the values of the variable can be ranked, it is measured on an ordinal scale. Examples are 
CHA2DS2-VASc score or education level. Numerical values can be measured on a ratio or 
interval scale. Examples are temperature, weight, age, and height. On a ratio scale there is an 
absolute zero, as for weight and height, and there can be no negative values. This allows a 
meaningful ratio to be calculated, i.e. a person who is 40 years old is twice the age of a 20- 
year old. Temperature in Celsius is measured on an interval scale, and similarly to the ratio 
scale each step is equidistant. An increase from 20 to 21 degrees Celsius is the same as an 
increase from 25 to 26.  
3.7.2 Statistical tests in our studies 
In our studies, nominal variables were descriptively presented in tables as proportions or 
frequencies; ordinal variables as medians with interquartile range; and numerical variables as 
means with standard deviation if the data was normally distributed. We compared two groups 
statistically using two sided test of proportions (pr-test) or the Chi2-test for nominal variables 
with only two values (dichotomous or binary). When comparing two groups with respect to 
nominal variables with more than two values or ordinal variables, we used the Chi2-test. For 
ordinal values, a Mann-Whitney test could have been used (and was used in some new 
analyses included in this thesis) instead of the Chi2-test. For numerical variables we used the 
student’s t-test to compare means between groups, granted that data was normally distributed.  
Our main outcome variable in all the studies was medication dispensation. Medication 
dispensation was defined as a dichotomous variable, i.e. the only data values for the variable 
were “1” or “0”. Because the outcome variable was dichotomous we used logistic regression. 
With logistic regression you can input multiple variables in the statistical model, and thus 
control for confounding. This is not possible with the pr-test or Chi2-test. For a more detailed 
discussion on the choice of confounding variables used in the models, please see the methods 
sections in the included manuscripts I-IV.  
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3.7.3 What are odds ratios? 
Logistic regression, which was used in all our studies, provides results in the form of odds 
ratios. Thus, it is important to understand what an odds ratio (OR) is. Imagine a cohort study 
which wishes to examine the association between an exposure, in this example smoking, and 
some form of cancer. In the 2x2 table in figure 8, the exposure and outcome data are 
presented. What are the odds of a smoker getting cancer?  Odds are defined as the probability 
(p) of an event occurring, divided by the probability of it not occurring (1-p). In this case the 
probability (p) of a smoker getting cancer is 5/100. The probability of a smoker not getting 
cancer (1-p) is 95/100. Using the definition of odds, it follows that the odds of a smoker in the 
study getting cancer is (5/95)/(95/100)=0.053. It also follows that the odds of a non-smoker 
getting cancer is (20/800)/(780/800)=0.026. The OR is the odds of a smoker getting cancer, 
0.053, divided by the odds of non-smokers getting cancer, 0.026. Thus, the OR is 
0.053/0.026≈2. An odds ratio of 2 in this example means that smokers have a twice the 
likelihood of getting cancer, compared to non-smokers. 
 
Figure 8. How to calculate the odds ratio. Example of exposure and outcomes in a prospective 
cohort study aiming to study the association between smoking and cancer. 
3.7.4 Missing data 
There was no obvious problem with missing data in the studies in this thesis. In study III and 
IV, mosaic data was missing in around 0.3% of patients. For some of the primary care 
variables, there were missing values in 0.3-1% of patients. In study I, information on 
education was not available in 6% of patients.  
3.8 ETHICAL CONSIDERATIONS 
3.8.1 Informed consent 
The Helsinki Declaration of ethical principles for research involving human subjects was first 
adopted in 1964 by the World Medical Association and has since been amended several 
times, most recently in 2013182. An important principle in the declaration is that of informed 
consent. The declaration states that all human subjects who take part in research and are 
capable of giving consent must give their informed consent to their participation. This means 
that research on human subjects must be voluntary. In large scale registry research it is often 
not possible, or at the very least incredibly impractical to obtain informed consent183.  
Our publications I-IV all included >10 000 patients (table 1). Our data set in study III and IV 
contained 108,806 patients before we applied exclusion criteria. There would be several 
problems with obtaining informed consent in this group of patients183. First of all it would be 
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very costly. Second, the practical difficulty of sending out letters containing information 
material and consent forms to hundreds of thousands of participants would be immense. 
Thirdly, requiring informed consent would lead to selection bias since the study would likely 
lose a considerable portion of the intended cohort. In the case of stroke, patients with 
cognitive difficulties may have a difficult time understanding information, and thus have 
difficulties giving informed consent. They may also have practical difficulties such as motor 
skill deficits which might make mailing signed consent forms more difficult. Stroke patients 
are a vulnerable group, which makes it all the more important to include them in a study. 
Losing a large proportion of patients would make the interpretation of the study results more 
challenging, limiting the external validity. Finally, the mere acquisition of informed consent 
by the researcher may influence patients’ medication use, making them more aware and 
likely to change their medication taking behavior.  
The basis for registry/database research being ethically acceptable despite the lack of 
informed consent is that data in registries/databases is anonymized. This was the case in all 
our studies. Data in the national healthcare registries and VAL is collected routinely, and 
collection is not influenced by research purposes. With anonymized data, the researcher 
cannot identify any individual in the study. If a study for some reason requires that a patient 
be identified, informed consent must be sought and acquired.   
In publication I, we cross-linked data from VAL with data from SCB. The cross-linking was 
performed at the NBHW. Thus, they must have a linkage key, which can identify patients and 
thereby permit the cross linkage. It is important to note that the researchers do not have 
access to the linkage key. Furthermore, linkage keys are destroyed if keeping them is not 
specially requested by the researchers. The ethics of this cross-linking of data I believe are 
solid, granted that the NBHW keep the linkage keys safe until they are destroyed. In 
publications II-IV we only used unidentified data from the VAL database, and no cross-
linking was performed. 
3.8.2 Personal integrity and the potential for identification in study III-IV  
In publications III and IV, there was a miniscule, but real, risk of patient confidentiality being 
breached, despite data in the primary care quality reports being anonymized and on a group 
level. The centers received data on medication use in their own stroke/TIA and atrial 
fibrillation patients. In very small primary care centers, there may have been a chance of the 
doctor identifying an individual patient’s medication use. However, for a patient to learn that 
they have been identified from the quality reports, it would require that a doctor give some 
indication of this identification in a patient consultation. Although it would seem unlikely on 
the doctor’s part, it may of course occur. If a patient’s confidentiality is breached, it may be 
construed by an individual patient as a breach of their personal integrity. How big was the 
problem in our study? In the cohort of patients in study III with previous ischemic stroke/TIA 
there were only four out of approximately 100 intervention centers with <10 ischemic 
stroke/TIA patients listed. These centers had nine, eight, seven, and four patients, 
respectively. Patients are easier to identify if the pattern of medication use in a center is “all 
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or nothing” – i.e. if all the patients in a center are, or are not, using a medication. If there is a 
mixed pattern of medication use with some patients using and others not, then identification 
of the individual patient becomes harder. The mixed pattern of use was more common in 
these smaller centers.  
We could have chosen to exclude all centers with <10 ischemic stroke/TIA patients. 
However, we felt that the overall positives in sending quality reports to all centers 
outweighed the negatives. Had some centers not received the reports this may have been 
construed as unjust and undermined the overall sympathy towards the “Quality Report 
Stroke” project. Furthermore, however disconcerting to the patient, the nature of the patient 
data which was at risk from a confidentiality breach cannot be considered as sensitive. The 
only data at risk was one variable, medication use, possibly in only one class of medication. 
A breach would have been more worrisome, had more data been included in the reports. 
Trying to be fair and wanting to supply quality data to all centers, together with the very 
small number of patients at risk of a confidentiality breach, led us to send the intervention to 
all centers in the intervention group. From a consequence ethics perspective, we believed this 
course of action was most sound.    
3.8.3 Depriving control centers of quality data 
According to a rights based ethics point of view, it may be argued that it was unethical to not 
supply quality data to all primary care centers in Region Stockholm, since they may be of 
value to patients in those centers. We, as researchers, believed that the intervention had the 
potential for improving patient outcomes, but we had no data to support this. Thus, launching 
a ubiquitous campaign with quality reports with an unknown effect would have been 
irresponsible towards tax payers. The resources that funded the quality reports could and 
should of course have been used elsewhere if the intervention was not beneficial. Thus, the 
main reason for it being ethical to withhold an intervention to a control group, in ours and in 
other studies, is that the effects of the intervention are not known. Moreover, to alleviate the 
absence of a potentially beneficial intervention in control centers, we sent quality reports to 
all primary care centers in Region Stockholm in 2017. This allowed all centers access to their 
quality data.   
3.8.4 The integrity of primary care doctors 
Potentially, the reports could have induced a feeling of “being watched” in the primary care 
center doctors. Receiving data their patients may have offended them, particularly if their 
patients happened to not be treated adequately. The concept may be viewed as a breach of 
some form of professional integrity. The consequences of this type of breach, I believe, are 
small when contrasted to the potential breach of patients’ personal integrity.   
3.8.5 Ethical permits 
The studies in this thesis were approved by the regional ethics committee in Stockholm. The 
following ethical permits were acquired: 2007/784-31/4 (study III and IV); 2010/1158-31/2 
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(study I, III and IV); 2015/803-31/5 (study II); supplementary permit 2016/1547-32  (study 
II); clarifying permit 2011/662-39 (study III and IV); clarifying permit 2016/1048-32 (study 





4.1 MEDICATION USE AFTER ISCHEMIC STROKE/TIA (STUDY I AND III) 
4.1.1 Medication use 9-12 months after ischemic stroke/TIA 
Use of statins 9-12 months after ischemic stroke/TIA was low in study I (diagnosis 2006-
2010) for both men, 49%, and women, 39% (table 2). In unpublished results, this contrasted 
to the use of antiplatelets which was high, 75% for men and 74% for women (table 2). The 
use of anticoagulants in patients with atrial fibrillation was low (table 2), for both men (42%) 
and women (32%). In an unpublished analysis, the sex difference in anticoagulant use was 
mainly due to women in the ≥80 age group being undertreated (28% men, 22% women). In 
the ≥80 group, the sex differences were statistically significant in a multivariate logistic 
regression analysis (unpublished), even after adjusting for income class, which likely was a 
confounder of the association (change in the OR of 8,6% when adjusting for income class). 
 
Table 2. Partially unpublished results. Comparison of sex differences in use of secondary 
preventive medication in patients with previous ischemic stroke/TIA in study I and III. Patients 
in study I had their ischemic event 2006-10 and patients in study III 2011-15. Medication use in study I 
was defined as one dispensation 9-12 months after the event and in study III as two dispensations in 
an 18-month period 2016-17. Differences tested with test of proportions/pr-test. Study I included 19 
335 patients and study III 12 766 patients. Anticoagulants in patients with atrial fibrillation, antiplatelets 
in patients without atrial fibrillation. 
 
4.1.2 Medication use after ischemic stroke/TIA over time 
The use of all classes of secondary preventive medications after ischemic stroke/TIA have 
increased over time over time when comparing data from study I and study III (table 2, 
partially unpublished results). The increase is most pronounced for anticoagulants and statins.  
4.1.3 Sex differences in medication use after ischemic stroke/TIA 
When comparing temporal differences in medication use with respect to sex (table 2, partially 
unpublished results), use of all medication classes has increased for both men and women. 
4.1.3.1 Anticoagulants 
The differences seen between women and men in study I for anticoagulants can no longer be 
seen in study III (table 2). Also, when analyzing all included patients with atrial fibrillation in 
  Study I 
2006-10 
  Study III 
2016-17 
 









Medication class         
Statins 44 39 49 <0.0001 66 60 72 <0.0001 
Antihypertensives  68 69 67  0.03 77 76 77 0.48 
Anticoagulants  37 32 42 <0.0001 86 86 86 0.50 
Antiplatelets  74 74 75 0.13 82 82 82 0.36 
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study III, there are no longer any statistically significant sex differences in anticoagulant use 
in any age group (appendix table A1, unpublished results).  
4.1.3.2 Statins  
Contrastingly, the differences in statin use are still present in study III, albeit with both sexes 
increasing their use (table 2). These sex differences in statin use in study III, can still be seen 
when performing multiple logistic regression analyses, and adjusting for comorbidities, 
socioeconomy, and age (unpublished results). In the fully adjusted model the OR was 0.60 
(95%CI 0.55-0.65) with an OR <1 meaning that women use less statins (unpublished results). 
Finally, statistically significant sex differences in statin use can be seen in all age groups 
(Appendix table A2, unpublished results).  
4.2 SOCIOECONOMY AND MEDICATION USE (STUDY I) 
 
Table 3. Partially unpublished results. Based on data from study I. Multivariate analysis of 
association between medication use 9-12 months, after ischemic stroke/TIA diagnosis 2006-10, 
and socioeconomic and demographic factors. Antiplatelets in patients without atrial fibrillation. 
Anticoagulants in patients with atrial fibrillation. Adapted from Geary et al. Sociodemographic 
factors are associated with utilisation of statins after ischaemic stroke/TIA. International 







(OR) [95% CI] 
Statins 
(OR) [95% CI] 
Antiplatelets 
(OR) [95% CI] 
Anticoagulants 
(OR) [95% CI] 
Age group 19-64 0.54 [0.50-0.59] 0.85 [0.79-0.92] 0.69 [0.63-0.76] 1.59 [1.26-2.00] 
 65-79 reference reference reference reference 
 >80 1.11 [1.02-1.20] 0.45 [0.41-0.48] 0.98 [0.89-1.08] 0.38 [0.33-0.44] 
Sex Men reference reference reference reference 
 Women 0.96 [0.90-1.02] 0.77 [0.72-0.82] 0.92 [0.85-1.00] 0.93 [0.80-1.07] 
  Income Highest 1.03 [0.94-1.12] 1.35 [1.24-1.47] 1.16 [1.04-1.29] 1.55 [1.28-1.87] 
 3rd quartile 1.06 [0.96 – 1.17] 1.18 [1.07-1.30] 1.09 [0.96-1.23] 1.37 [1.11-1.69] 
 2nd quartile reference reference reference reference 
 Lowest 1.00 [0.85-1.18] 0.84 [0.72-0.99] 0.79 [0.66-0.95] 0.93 [0.64-1.35] 
Education High 0.89 [0.82-0.96] 1.03 [0.95-1.11] 0.90 [0.82-1.00]  1.01 [0.85-1.21] 
 Medium reference reference reference reference 
 Low 1.10 [1.02-1.19]  0.90 [0.84-0.97] 1.04 [0.95-1.15]  0.85 [0.73-1.01] 
Country of birth Sweden reference reference reference reference 
 Nordic 1.10 [0.97-1.24] 0.97 [0.86-1.09] 0.90 [0.78-1.04] 0.97 [0.74-1.28] 
 Europe 0.87 [0.77-0.99] 1.02 [0.90-1.16] 0.96 [0.82-1.13] 0.87 [0.64-1.18] 
 Outside Europe 0.69 [0.58-0.81] 1.05 [0.89-1.24] 0.80 [0.66-0.97] 0.94 [0.56-1.56] 
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In study I, statin use was low (44%). Thus, statins became the focus of the study. However, 
we studied the use of all recommended secondary preventive medications 9-12 months after 
ischemic stroke/TIA (antiplatelets in patients without atrial fibrillation, anticoagulants in 
patients with atrial fibrillation). In the partially unpublished multivariate analysis in study I 
(table 3), education, income, sex, and age were associated with statin use 9-12 months after 
ischemic stroke/TIA. Patients in the lowest education class were less likely to use statins than 
patients in the medium class. Patients in the two highest income classes were more likely to 
use statins than patients in the second lowest income class, who in turn were more likely to 
use statins than patients in the lowest income class. Patients in the age group 65-79 were 
more likely to use statins than both patients of lower and higher age. Men were more likely to 
use statins than women.  
Patients in the highest income group (and second highest for anticoagulants) were more likely 
to use antiplatelets and anticoagulants, than patients in the second lowest income group.  
Patients in the youngest age group were more likely to use anticoagulants, and the eldest age 
group (≥80) less likely, compared to patients aged 65-79. Low education was associated with 
using more antihypertensives. Patients born in Europe outside of the Nordic countries were 
less likely to use antihypertensives. Patients born outside Europe were less likely to use both 
antihypertensives and antiplatelets.   
I performed a new multivariate analysis (unpublished results) on the dataset from study I, 
focusing only on statin use in ischemic stroke patients (Table A3 in appendix). This analysis 
did not differ much from the original one (table 3). The new analysis was performed to allow 
for comparison with another Swedish publication184 which studied socioeconomy and statin 
prescription after ischemic stroke.  
4.3 ANTICOAGULANT USE IN ATRIAL FIBRILLATION (STUDY IV) 
4.3.1 Anticoagulant use over time 
Anticoagulant use in patients with atrial fibrillation has increased from 2014-15 to 2016-17 in 
Region Stockholm. In atrial fibrillation patients with CHA2DS2VASc score ≥2, 77% of men 
and 75% of women used anticoagulants in 2014-15, 83% of men and 81% of women in 
2016-17. In unpublished results, the increase has likely been largest in the age group ≥85, 
where anticoagulant use increased from 71% to 79% (appendix table A4).   
4.3.2 Age differences 
There were some age differences in the use of anticoagulants in patients with atrial 
fibrillation, with the highest proportion of treated patients being in the age group ≥65 
(unpublished results, table A4). The proportion of patients who used anticoagulants in the 
youngest age groups, 18-54 and 55-64, depended on how the CHA2DS2VASc score was used 
to include patients (table A4). For example, in 2016-17, 65% of patients aged 18-54 with 
CHA2DS2VASc ≥2 used anticoagulants, and 75% of patients if the CHA2DS2VASc score 
was ≥2 in men and ≥3 in women (table A4).  
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4.3.3 Sex differences 
In supplementary table 6 in study IV, a multivariate logistic regression model showed that 
women with atrial fibrillation diagnosis in 2011-15 were less likely to use anticoagulants than 
men in 2016-17. In an unpublished analysis, characteristics between women and men with an 
atrial fibrillation diagnosis in 2011-15 differed somewhat (appendix table A5). Women were 
older than men and had a lower prevalence of diabetes, heart failure, hypertension, and 
previous myocardial infarction. Fewer women than men were treated with statins. 
Anticoagulant use was 83% in men with CHA2DS2VASc score ≥2, and 82% in women with 
CHA2DS2VASc score ≥3 (unpublished data). Patients with CHA2DS2VASc ≥2 for men and 
≥3 for women were further analyzed with multivariate logistic regression with the same 
adjustment models used in the original publication (unpublished analysis). The sex 
differences were no longer statistically as the 95% confidence interval included 1 - OR 0.93 
(95% CI, 0.87-1.00). Sex differences in the youngest age groups depended on which 
CHA2DS2VASc scores were used to include patients (table A4). In the age groups ≥65, the 
absolute sex differences in use of anticoagulants in 2016-17 were small, and there were no 
statistically significant differences (table A4).    
4.4 DIAGNOSIS RECORDING (STUDY II-IV)  
4.4.1 Study II 
Diagnosis recorded patients were more likely to use statins in both ischemic stroke (OR 1.58, 
CI 1.42-1.76), TIA (OR 1.53, CI 1.28-1.82), and ACS (OR 1.64, CI 1.47-1.83). The 
association was even stronger when studying antithrombotics. Both recorded men and 
women were more likely to use statins and antithrombotics. For antihypertensives the pattern 
of the association was more unpredictable. Men with a recorded ischemic stroke diagnosis 
were more likely to use antihypertensives, whereas women with a recorded TIA diagnosis 
were less likely.   
4.4.2 Study III and IV 
4.4.2.1 Diagnosis recording of ischemic stroke/TIA (study III) 
Diagnosis recording of patients with ischemic stroke or TIA increased over time from 
dispensation period A (2014-15) to B (2016-17), but the absolute proportions of diagnosed 
patients were still low, particularly for TIA (table 4, partially unpublished analysis). Patients 
in intervention centers with TIA were statistically more likely to be recorded than patients in 
control centers after, but not before, the intervention. The absolute differences were small. 
For ischemic stroke, there were no statistically significant differences in diagnosis recording 
between control and intervention center patients before, or after, the intervention (table 4, 




Table 4.  Partially unpublished results, based on data from studies II-IV. Proportion of patients 
with a recorded diagnosis in primary care in Study II and during dispensation periods 
(A=140701-151231, B=160101-170630) in studies III and IV. By intervention status (for study III and 
IV) and diagnosis. Patients with atrial fibrillation had a CHA2DS2VASc score ≥2. For study III and IV, 
index diagnosis 2009-14 (A) or 2011-15 (B). For data on methodology used for diagnosis recording in 
study II please see original publication or other sections of this thesis. Differences tested with Chi2-
test.  
4.4.2.2 Erratum in study III 
Due to a programming oversight, which only affected the results for diagnosis recording, the 
absolute numbers for TIA and ischemic stroke recording were too low in the supplementary 
material in study III. The correct numbers can be seen in table 4. We also reported in study III 
that there was a statistically significant difference in diagnosis recording of TIA between 
intervention and control centers after, but not before, the intervention. In the corrected 
analysis the odds ratios for the associations have changed slightly, but showed the same 
overall results. A correction, with the new analyses, has been sent to Acta Neurologica 
Scandinavica.  
4.4.2.3 Diagnosis recording of atrial fibrillation (study IV) 
Diagnosis recording for atrial fibrillation patients with CHA2DS2VASc ≥2 was significantly 
higher than in patients with ischemic stroke or TIA (table 4, unpublished analysis). There 
were slight, but statistically significant differences between intervention and control centers 
in diagnosis recording after, but not before, the intervention.  
4.4.2.4 Characteristics of diagnosis recorded and non-recorded patients  
In a new analysis of data from study III, I compared characteristics of recorded and non-
recorded patients with ischemic stroke. Recorded patients were more likely to be men, and 






p All Centers  
in Region  
(%) 
TIA 
(Study II & III) 
    
Dispensation period A 
(n=5 577) 
10 11 0.66  
Dispensation period B 
(n=5 473) 
18 16 0.02  
Study II (n=4 214)    16 
Ischemic stroke 
(Study II & III) 
    
Dispensation period A 
(n=8 174) 
34 34 0.50  
Dispensation period B 
(n=7 796) 
44 43 0.53  
Study II (n=6 295)    44 
Atrial fibrillation (study IV)     
Dispensation period A 
(n=29 948) 
68 68 0.82  
Dispensation period B 
(n=31 477) 
74 72 0.001  
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used more statins, antihypertensives, and antiplatelets (appendix table A6). Recorded TIA 
patients used more statins and antiplatelets; were slightly older; and had less atrial fibrillation 
and diabetes (table A6).  
In another new analysis of data from study IV, I compared characteristics of recorded and 
non-recorded patients with atrial fibrillation and a CHA2DS2VASc score of ≥2 (appendix 
table A7). Recorded patients were older; had higher CHA2DS2VASc scores; used more 
antihypertensives and statins but less antiplatelets; had lower prevalence of previous 
myocardial infarction; but a higher prevalence of heart failure and hypertension. Recorded 
patients used anticoagulants to a much higher degree (92%), than non-recorded patients 
(54%). 
4.5 THE AUDIT & FEEDBACK INTERVENTION (STUDY III AND IV) 
4.5.1 Study III 
The audit & feedback intervention showed neutral results on medication use in patients with 
previous ischemic stroke/TIA (table 4 in study III). A sensitivity analysis defining medication 
use as 2-6 dispensations in the 18-month dispensation period was performed and did not 
change the results (supplementary material in study III). Also, two sub-group analyses were 
performed, neither of which showed any effect of the intervention (supplementary material in 
study III). One of these subgroup analyses compared intervention centers that potentially used 
the reports, and the control centers. The other compared the centers that may have used the 
reports with the other intervention centers.    
4.5.2 Study IV 
In the multivariate logistic regression analysis, patients with atrial fibrillation in intervention 
primary care centers were more likely to use anticoagulants than control center patients after, 
but not before, the intervention. However, when comparing odds ratios before and after the 
intervention, differences were small (table 2 in study IV). Also, the absolute differences were 
small. The before-after proportion of patients using anticoagulants was 76-81% in control 
centers and 77-83% in intervention centers. In an analysis including only women, 
intervention center patients were more likely to use anticoagulants after, but not before, the 
intervention (table 3 in study IV). The difference in odds ratios before and after the 
intervention was slightly larger than in the main analysis. However, similarly to the main 
analysis, absolute differences between intervention and control center patients were small. 
Before the intervention, 74% of women in control centers and 75% in intervention centers 
used anticoagulants (unpublished results). After the intervention those same proportions were 
80% for control center patients and 82% in intervention centers (unpublished results).  
Similarly to the analysis in study III, a sensitivity analysis of different number of 
dispensations defining medication use, did not change the results (supplementary material in 
study IV). The same two subgroup analyses as in study III were performed, neither showing 
any clear effect of the intervention (supplementary material in study IV). Also, patients ≥75 
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years of age were specifically analyzed and results were similar to the main analysis 
(supplementary material in study IV). Finally, results were nearly identical to the main 






5.1 SOCIOECONOMY, DEMOGRAPHY, AND THE USE OF STATINS 
5.1.1 Main results for all medication classes 
In study I, we found that higher income was associated with using more statins, antiplatelets, 
and anticoagulants (in patients with atrial fibrillation and stroke) 9-12 months after an 
ischemic stroke/TIA in 2006-10. Patients in the youngest age group (18-64) used less of all 
medication classes except anticoagulants, which were used more. Low education was 
associated with using less statins but more antihypertensives. The variable “country of birth” 
was hard to analyze and interpret as the groups were large and heterogeneous, for example 
“outside Europe”. Women used less statins. 
5.1.2 Focus on statins and income 
Statins are the secondary preventive medication class which is used the least. Anticoagulants 
were also used sub-optimally in study I. However, it has become clear that anticoagulant use 
has increased significantly from the numbers we reported in study I. Thus, given that 
antihypertensives, antiplatelets, and anticoagulants show a relatively high level of use, any 
socioeconomic differences are likely to be most important for statins. Thus, I have chosen to 
focus on statins in this discussion, and income in particular, since the association between 
statins and income showed a clear stepwise gradient in study I.   
5.1.3 Other Swedish studies of statin use 
5.1.3.1 Prescription and adherence and the association with socioeconomy and 
demography 
Two other Swedish registry studies have studied socioeconomic factors and statin use after 
ischemic stroke51,184. One of the studies focused on factors associated with prescription of 
statins at discharge184, and the other on factors associated with two-year adherence in all 
patients prescribed a statin at discharge51. I performed a new (unpublished) analysis using the 
dataset from study I (table A3), including only the patients with ischemic stroke. The new 
analysis showed that many factors associated with statin use in our study at 9-12 months, 
were also associated with statin prescription at discharge184. Being female was associated 
with both lower prescription at discharge and lower use after 9-12 months. High income and 
high education were associated with higher prescription and use after 9-12 months. 
Contrastingly, prescription was lower in the 70-79 age group compared to the 18-59 group, 
while statin use after 9-12 months was higher. Both prescription and medication use after 9-
12 months were lower in the ≥80 age group. The study of statin adherence51 found that 
women were less adherent and also that higher out of pocket costs were associated with lower 
adherence51. Higher income was associated with better adherence to statins, but the 
association was not statistically significant on multivariate analysis51.    
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5.1.3.2 Relevance of comparing prescription, medication use, and adherence? 
Prescribing; medication use in all patients in a certain time period (study I); and adherence 
are different outcomes. For prescribing, all patients with ischemic stroke were studied184, as 
was also the case in study I. In the study of statin adherence only patients who were 
prescribed statins were studied51. The factors associated with doctors choosing to initiate 
treatment after stroke may differ from factors associated with patients using the medication in 
the long term. An example of this is that patients born in Sweden were less likely to receive a 
statin prescription184, but more likely to be adherent51. Thus, while it may be interesting to 
compare socioeconomic and demographic factors that influence prescription, medication use, 
and adherence, any direct comparisons should be interpreted with caution.  
5.1.4 Income and statin use in other settings 
5.1.4.1 Income may be associated with regimen persistence in ischemic stroke/TIA 
International studies on the association between income and statin use after stroke specifically 
are lacking. Bushnell et al studied persistence and adherence to a regimen of secondary 
preventive medications in patients with ischemic stroke/TIA in the US58. They found that 
patients having insurance and having an income that adequately met their household needs 
were associated with increased likelihood of being regimen persistent and adherent.  
5.1.4.2 Income and statins in primary and secondary prevention of cardiovascular disease 
Similarly to our study, other studies in varying populations in high income countries have 
described an association between higher income and better statin use. Studies of medication 
use in myocardial infarction patients in Canada and Denmark have shown an association 
between higher income and better statin use185,186. The same association has been seen in 
studies of primary prevention from Denmark and Finland187,188. One of the studies showed 
sex differences, with the association between income and statin use only being observed in 
men187. Studies with mixed primary/secondary prevention cohorts have found somewhat 
differing results189-192. Two studies, from Sweden and the US respectively, found higher 
income to be associated with better use of statins189,190, while an Israeli and an Australian 
study found no such association191,192. The lack of association with income in the Israeli study 
is hypothesized by the authors to be due to the low level of co-payment191. 
Finally, studies on statin use from the US in both a mixed primary/secondary prevention 
cohort193 and a coronary heart disease cohort194, indicate that lower co-pay may be associated 
with higher use of statins193,194.  
5.1.5 Income associated with medication use in Sweden despite subsidies 
and cheap drugs  
The fact that lower income is associated with lower medication use of several medication 
classes is somewhat surprising since medications are relatively cheap, and medicine is 
subsidized in Sweden195.  
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5.1.5.1 Equivalized disposable income  
The exposure variable “income” in study I was equivalized disposable income (EDI). EDI is 
a concept that was created to be able to compare the economic conditions of households with 
different compositions, i.e. single people; married people without children; married with a 
specific number of children etc196,197. The rationale is that there are advantages of 
cohabitating, in that consumption in the household becomes cheaper per capita. Thus, to be 
able to compare households, incomes are weighted. EDI is calculated as the sum of all 
positive income minus taxes (any potentially other negative transactions) in the household, 
and is then weighted by household composition196. The EDI in the lowest income quartile in 
study I was <108 000 SEK in 2009, and >200 000 SEK in the highest quartile.   
5.1.5.2 Cheap medication costs with generic options 2007-2011 
Simvastatin became generic before the start of the period of dispensation in study I198, and the 
cost of a daily dose of simvastatin started at 50 öre (0,5 SEK) in 2009199. Aspirin is a 
medication that has been available for many years and is cheap. Currently 100 tablets of 
aspirin (Trombyl®) 75 mg costs 62 SEK200.  
5.1.6 Summary of the association of income and statin use after ischemic 
stroke/TIA in Sweden 
The differences in statin use between income groups in study I remained after multivariate 
analysis with adjustment for potential confounders such as age group and sex. Sjölander et al 
also showed that higher out of pocket cost, i.e. the cost which was not subsidized, was 
associated with lower adherence to statins after ischemic stroke51. Taking into account the 
statistics on EDI, it still seems odd that patients would not be able to afford a statin, which 
would have cost no more than around 300-400kr/year. EDIs are not weighted for region, and 
Stockholm may be more expensive than other regions and thus may make income more 
important. In conclusion, taking into account both national and international studies, it cannot 
be excluded that income in itself may have been a factor which influenced statin use at the 
time of study I. However, it must be appreciated that other unknown factors related to income 
may have contributed to the association.  
5.1.7 How is the awareness of income inequality useful? 
Knowledge of income inequality in medication use is of limited use clinically, but may be 
useful in the planning of national medication subsidization. While there is no current 
evidence to suggest that reducing the level of co-pay would increase statin use in our setting, 
it is an interesting idea if income inequality persists in newer studies. Alternatives to the 
current system where subsidies start at 1100 SEK, could be to start subsidizing earlier, or 
from 0 SEK.  
5.1.8 Are the socioeconomic associations dynamic over time? 
Since medication use after ischemic stroke/TIA has improved considerably over time it is 
possible that the association between socioeconomic factors and medication use may also 
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have changed. Also, disposable income may change over time. The previously mentioned 
study on prescription and socioeconomy included patients in 2004-2009, when only 46% of 
stroke patients were prescribed statins184. In 2019 statins were prescribed to 81% of stroke 
patients2. The study on adherence and socioeconomy included patients from 2009-201051. 
Repeating these studies against a baseline of higher mediation use would be interesting to see 
for example if income inequalities persist.  
5.2 USE OF ANTIPLATELETS AND ANTIHYPERTENSIVES REMAINS HIGH 
Use of antiplatelets and antihypertensives remains high in Region Stockholm. 82% of 
patients with previous ischemic stroke/TIA (without atrial fibrillation) use antiplatelets and 
77% use antihypertensives. When medication use is defined as five dispensations in 18 
months it remains high, 68% using antiplatelets and 71% antihypertensives. For statins, 
medication use drops to 51% when defined as five dispensations (appendix table A8).  
5.2.1.1 Antihypertensives – more complicated to interpret than the other classes 
Antihypertensives are different than the other secondary preventive medication classes in that 
medication use was defined as two dispensations of any antihypertensive medication. With 
statins and antiplatelets the recommended daily dose will generally be just one tablet. Patients 
treated with antihypertensive treatment may be on one of many different medication 
regimens, which may change over time. Hypertensive patients often require more than one 
class of antihypertensive drug to treat their hypertension201,202. Furthermore, recent guidelines 
published in 2018 recommend that most antihypertensive patients requiring treatment should 
be started a combination of two antihypertensive drugs rather than monotherapy202. 
Consequentially, being dispensed antihypertensives twice in 18 months could mean several 
things. For example, a patient could have tried two different medications and then stopped 
using them. An example could be a patient trying an angiotensin converting enzyme (ACE) 
inhibitor, experiencing side-effects, switching to an angiotensin II receptor blocker (ARB) 
and stopping it because of more side-effects. Also, being dispensed four times during the 18 
months could mean being on one medication at the start of the 18 months, and then being 
dispensed additional classes of antihypertensive medications during the rest of the period.  
5.2.1.2 Measurable goals in antihypertensive treatment 
Another way in which antihypertensives are different compared to most other secondary 
preventive medication classes, is that there are measurable hypertension goals for treatment 
which are applicable to most patients15. It is of course possible to measure blood low-density 
lipoprotein (LDL) levels as a marker of statin effect. While there may be LDL targets in the 
future in stroke203, these are not yet established. Furthermore, recent guidelines support the 
use of statins in all patients, regardless of LDL level204. Contrary to LDL targets, a blood 
pressure target of <90 diastolic and <140 systolic are well established in secondary 
prevention of ischemic stroke/TIA15,202.  
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5.2.1.3 High use of antihypertensives without reaching blood pressure targets  
A large proportion of patients with previous ischemic stroke/TIA use antihypertensives. 
However, it is well established that many patients with hypertension with or without previous 
ischemic stroke do not reach treatment goals65,205-207. Thus, from a secondary stroke 
prevention perspective, dispensation data is not enough to determine how many 
antihypertensive medications the individual patient needs to be using to achieve blood 
pressure goals. Also, some patients may not be treated with antihypertensives since they have 
an optimal blood pressure. Future studies of antihypertensive treatment after ischemic 
stroke/TIA would benefit from utilizing data on blood pressure levels from primary care. It 
would be interesting to study the patterns of antihypertensive medication use in patients 
achieving and not achieving blood pressure targets.  
5.3 STATIN USE STILL SUBOPTIMAL AFTER STROKE 
5.3.1 Statin use in Stockholm is still suboptimal 
Statin use after ischemic stroke/TIA has improved over time in Region Stockholm but is still 
not optimal. Study I and III are somewhat different methodologically but it is clear that statin 
use has increased, being 66% in III (ischemic stroke/TIA diagnosis 2011-15). The NBHW 
has set a target of ≥80% of patients using statins 12-18 months after ischemic stroke or TIA18. 
The target is defined as patients being dispensed statins at all in the time period 12-18 
months. Thus, patients are still not optimally treated.  
5.3.2 Age differences in statin use 
While statin use is not optimal in any age group in the cohort of ischemic stroke/TIA patients 
diagnosed 2011-15 in Region Stockholm (study III), it seems to be highest in the 65-79 age 
group (table A2). Only 45% and 56% of patients aged 18-54 and ≥85, respectively, used 
statins. Thus, it seems that increasing statin use is most urgent in the youngest and the oldest.  
5.3.3 Comparison with national Swedish data 
Comparing with other Swedish data is difficult due to methodological and temporal 
differences16,51. Previous Swedish studies with national data have reported two-year statin 
adherence51 and persistence16, respectively, after ischemic stroke. Two years adherence, 
defined as a PDC of ≥80%, was 74%51, while two-year persistence was 56%16. As previously 
mentioned in this thesis, it is hard to compare persistence; adherence; and multiple 
dispensations in a time period in all patients. However, it should be mentioned that, similarly 
to our study on medication use, adherence to statins was lowest in the 18-54 and ≥85 age 
groups51.  
5.3.4 Statin use internationally 
There is room for improvement of statin treatment after ischemic stroke in Sweden, but other 
countries, regardless of continent, seem to be in greater need of improving statin 
use10,16,34,43,51,57-59,65,90-92,208,209. I performed a literature search in August 2020, which 
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identified 16 studies reporting on the use of statins after ischemic stroke/TIA (appendix table 
A10). Six of them, including study I and III, are from Sweden. The studies on statin use are 
generally of high quality, and are not subject to all of the limitations affecting studies on other 
medication classes, as previously mentioned in section 1.4.2.5.  However, similarly to what 
was described in the background section, studies are heterogeneous with regard to method for 
studying medication use; duration of follow up; geographical area; and time period. As has 
previously been discussed in this thesis it is important to know what is being studied - 
adherence, persistence, or medication use in all patients. The study of persistence or 
adherence does not all include all patients, only those who have started treatment.  
Of the ten international studies, five focused on persistence, one on adherence and four on 
medication use in all patients (table A10). Persistence ranged from 38-76%, the highest 
number seen in a US study, where participating hospitals were involved in an “improving 
stroke care”-program (Get With The Guidelines Stroke)58. The only study using adherence as 
an outcome found 66% of statin users to be adherent90. Medication use of statins ranged from 
8-60% in the four identified studies, where the lowest use was seen in a Chinese cross-
sectional community study208. The very low proportion of users (8%) likely reflects both sub-
optimal care in China, and the duration of time after the index event when medication use 
was registered (median 48 months). It should also be noted that statin use in South America 
after stroke seems to be very low209 with only around 10% of patients treated. 
5.4 STATINS ARE STILL USED MORE BY MEN 
5.4.1 Sex differences in statin use 
Men use statins more than women after ischemic stroke/TIA in Region Stockholm. In 
patients with an ischemic stroke/TIA diagnosis 2011-15 (study III), 72% of men and 60% of 
women used statins. Multiple studies have shown that women with established, or at risk for, 
cardiovascular disease use statins less than men184,210-214. An American study of 6 000 
patients in community practice reported sex differences in several interesting parameters of 
statin use210. These sex differences included women being less likely to have been prescribed 
a statin (67% vs 78%); less likely to use the recommended treatment intensity (37% vs 45%); 
more likely to have never been offered statins (19% vs 14%); and more likely to have 
discontinued their statin (11% vs 6%)210.   
5.4.2 Sex differences in statin use over time in Stockholm 
The absolute proportion of patients in Region Stockholm with previous ischemic stroke/TIA 
using statins has increased over time for both sexes, yet the sex gap remains. The differences 
in statin use between men and women are both statistically significant, and clinically relevant, 
in all age groups.  
5.4.3 Statins are equally effective in men and women 
Men and women derive equal benefit from statin treatment, with lower rates of 
cardiovascular events seen with statin treatment215,216. The fact that both sexes benefit from 
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statins makes the difference in statin use seen between sexes both in Sweden and 
internationally all the more concerning.  
5.4.4 Women are prescribed less statins after ischemic stroke in Sweden 
In addition to being dispensed less statins in the long term after ischemic stroke, women are 
initially prescribed less statins than men. This prescribing difference has been consistent over 
time. A Swedish national study of all patients with ischemic stroke between 2004 and 2009 
showed that men were prescribed more statins at discharge from hospital, 52% vs 41%184. In 
2019, 81% of patients in Sweden were prescribed a statin after ischemic stroke, 88% of men 
and 70% of women2. The sex differences were most pronounced in patients ≥ 80 years of 
age2. Statin prescription in all ischemic stroke patients in the seven hospitals in Region 
Stockholm ranged from 72-83% in 20192. There are no reasons to believe that the sex 
difference seen nationally would be absent in Stockholm.  
5.5 REASONS FOR SUB-OPTIMAL STATIN USE  
5.5.1 Reasons for sub-optimal statin use in general 
5.5.1.1 Side-effects 
Statins can produce muscle related side-effects217 which are often given as a reason for 
stopping statin therapy218,219.  Thus, they may be an important reason for suboptimal statin 
use. Furthermore, muscle related side-effects seem to be more common in observational trials 
than in randomized controlled trials (RCT)220,221. This discrepancy between RCTs and 
observational studies may stem from the absence of a consistent definition of statin associated 
muscle symptoms, together with selective exclusion criteria in RCTs220,221. Although there 
are some exceptions222, muscle related side-effects in RCTs of statins are relatively 
uncommon, with equal frequency in the statin and placebo groups220,221,223,224. For example, 
In the SPARCL trial of 80 mg Atorvastatin vs placebo in ischemic stroke patients the 
frequencies of muscle related side-effects over 5 years were 5.5% in the atorvastatin group vs 
6% in the placebo group224. However, some observational studies have shown higher 
frequencies of muscular side-effects ranging from 8% to around 25%218,225,226. This relatively 
high frequency of side-effects may be important. Studies have shown that stroke patients are 
concerned about side-effects of medications227, that concerns about medications is associated 
with higher non-adherence78,79,83, and that the absence of side-effects may be a facilitator of 
good medication use228.  
5.5.1.2 Controversy surrounding benefit in the elderly 
The benefits of statin treatment in the elderly has been questioned since studies on the 
secondary prevention of cardiovascular disease have often included very few older 
patients229. The definition of old is not always clear. Current ESC guidelines on the secondary 
prevention of cardiovascular disease recommend that old patients receive statins for 
secondary prevention of cardiovascular disease, but define “old” as patients ≥65 years204. A 
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meta-analysis from the Cholesterol Treatment Trialists’ Collaboration (CTTC) in 2019 
showed that older patients, ≥75 years of age, derive benefit from statins as secondary 
prevention, albeit with a trend towards lower effect for some outcomes than younger 
patients230. The available data on the effect of secondary prevention in elderly stroke patients 
is however still limited. In the CTTC study, the majority of secondary prevention patients had 
previous ischemic heart disease, and the authors do not specify if any patients with ischemic 
stroke were included230. Also, there is no specific data on the very old, ≥85, a group in which 
only 49% of patients with ischemic stroke/TIA in Region Stockholm 2011-15 were treated. 
Furthermore, patients in the SPARCL study which compared atorvastatin 80 mg vs placebo 
for the secondary prevention of ischemic stroke/TIA had a mean age of only 63224. To my 
knowledge there are no randomized studies in patients with prior ischemic stroke/TIA that 
have specifically studied older patients. In conclusion, while it may be reasonable to treat 
patients with previous ischemic stroke/TIA ≥75 years of age with statins, the risk/benefit in 
the very old is still unclear and individualization of treatment may be warranted. 
Individualization does not necessarily mean abstaining from treatment, but can also mean 
choosing to treat, but with lower doses of statins.  
5.5.1.3 The nocebo effect and negative media coverage 
The nocebo effect, i.e. the inverse of placebo, has been suggested as a contributor in 
suboptimal statin use231,232. Furthermore, negative media coverage of statins may increase the 
likelihood of patients discontinuing statins233-235.   
5.5.2 Reasons for sub-optimal statin use in women 
5.5.2.1  Side-effects and beliefs? 
The reasons for the lower statin use in women after ischemic stroke are not clear. Moderate to 
severe myopathy may be more common in men236. Possibly, women could have a higher total 
burden of muscle symptoms leading to them discontinuing their statin218. This is however 
speculative since there are conflicting studies226. It has also been suggested that women may 
have different beliefs concerning statins than men210, thus potentially making them more 
likely stop treatment. Women may be less likely than men to believe that statins are safe 
(48% vs 55%) and that they are effective (68% vs 73%)210. Finally, one study showed that 
more women than men give side-effects as the reason for stopping a statin218.  
5.5.2.2 Non-prescription 
Non-prescription at discharge after the index stroke may lead to enduring sex differences. 
The decision to treat with a statin is often made by neurologists or stroke specialists in 
hospital and may influence future prescription decisions in primary and secondary care. 
5.5.2.3 Age differences 
Finally, it must be noted that women with ischemic stroke/TIA are older than men and the 
very old are treated to a lesser degree with statins. A majority, 61% of patients in the ≥85 age 
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group with a previous ischemic stroke/TIA diagnosis in 2011-15, were women in study III 
(unpublished results). 
5.6 BENEFICIAL INTERVENTIONS IN THE LITERATURE TARGETING STATIN 
USE  
5.6.1 Several studies have shown benefit 
A Cochrane systematic review of interventions aimed at increasing statin adherence found 
several potentially beneficial interventions237. Interventions with beneficial effects were those 
with “intensified patient care”; a fixed-dose combination strategy (FDC), also known as 
“poly-pill”; and an automated refill reminder intervention237. Secondary preventive studies 
included in the review (nine out of 35) focused mainly on ischemic heart disease238-245. Only 
two out of nine studies with mixed primary/secondary prevention stated proportion of 
patients with prior cerebrovascular disease246,247. The proportions were 13%246 and 16%247, 
respectively.  
5.6.2 Fixed-dose combination interventions 
Four out of five trials using FDC found better adherence in the intervention group than 
control group238,246-248. The FDC consisted of aspirin, a statin, and antihypertensive 
medication238,246-249. The treatment in the control groups were either usual care or the 
individual drugs238,246-248. The one study which did not report a positive outcome only studied 
proportion of patients discontinuing treatment249. The comparator was placebo, which may 
not be equivalent to a real life situation where poly-pills will likely be used instead of the 
individual components249.    
5.6.3 Intensified patient care interventions  
Several studies using intensified care interventions reported benefit on statin use240,241,243,250-
259. Interventions in the group “intensified patient care” were heterogeneous. They often 
involved pharmacists delivering patient feedback and information243,250,252,259. Two studies 
used short message service (SMS) reminders240,257, and one provided calendar reminders for 
better medication use255. Another two studies had intensified follow up by telephone241,254. 
Two studies used automated phone calls to target patients who had not picked up 
prescriptions251,258. One study provided individualized risk factor profiles, and targets for 
improving risk profile, in context of increased nurse-led follow up at 3, 9, and 18 months 
following baseline256. Another study in primary care randomized patients to usual care or to 
education material and follow up visits every eight weeks for 48 weeks. Finally, one study 
used a multifaceted approach with education at discharge from hospital, primary care center 
contact, and structured pharmacist follow up at one week and one month243.  
5.6.4 Which of the beneficial interventions are useful for our purposes?  
Many of the beneficial interventions require significant resources, thus limiting their 
application on a larger scale. Also, some interventions are based on monitoring an individual 
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patient’s dispensations which is not possible in Sweden. Many studies involved pharmacist 
follow up, a function that, to my knowledge, is not practiced on a larger scale in Sweden. The 
interventions that seem most applicable to our setting are the use of a FDC strategy, and 
telephone and SMS reminders. How to incorporate such strategies in an intervention with the 
aim of increasing the total population use of statins is not obvious.   
5.7 IMPROVING STATIN USE AFTER STROKE 
This section summarizes some areas which could be targeted to improve statin use after 
stroke on a larger scale. An FDC strategy and/or SMS-reminders may have a role to play but 
are not mentioned further in this section. 
5.7.1 Helping patients cope with side-effects 
5.7.1.1 Information to patients regarding potential side-effects 
Since side-effects are a common reason for discontinuation of statin therapy218,219, helping 
patients to cope with them may be an important step in increasing statin use. A qualitative 
study revealed that patients feel that their concerns regarding side-effects are not always 
addressed by their doctors227. Thus, making sure patients feel informed of what side-effects 
may occur and how they can be handled could important. 
5.7.1.2 Physician tools for handling side-effects 
 If side-effects do occur, there are structured strategies which may be applied by the 
clinician260. In the Region Stockholm online guideline resource for primary care, there is 
already a section on how to handle statin side-effects (www.viss.nu)261, currently nested 
under the main subject of “hyperlipidemia”. These guidelines for statin side-effects may need 
to be advertised more clearly and made even more easily accessible, possibly by creating a 
main subject entitled “statin side-effects”.  
5.7.2 Clinical decision support systems 
Physician prescribing and motivating of patients could be targeted through a clinical decision 
support (CDS) system incorporated in the EMR. CDS systems in the context of medication 
use can work by giving the treating doctor a warning in the EMR when a patient with a 
certain registered diagnosis (e.g. ischemic stroke) is not being treated with a specific 
medication (e.g. statins)106. A prerequisite for CDS systems to work is that doctors can 
identify which patients the CDS system is applicable to. For this purpose, diagnosis recording 
in the EMR may become important.  
CDS systems have, to my knowledge, not been studied specifically to improve utilization of 
statins in patients with previous stroke. CDS systems in an EMR have however shown 
potential in increasing the use of anticoagulants in atrial fibrillation patients in primary 
care106. CDS systems have also been studied with some promise in the primary care setting in 
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the context of statin use in diabetics262, and in patients at high cardiovascular risk263. 
Interestingly, audit & feedback was a component of both studies.   
5.7.3 Personalized patient feedback  
The patient perspective is of course of importance and should be targeted. Personalized 
patient feedback may have a role to play256,264, as is described in a systematic review on 
RCTs attempting to increase statin use in primary prevention264. Interestingly, a Swedish 
primary prevention RCT randomized patients in the intervention arm to view their own 
carotid ultrasound results265. This led to an increase use of self-reported statin use after 1 year, 
with a 9% absolute difference between intervention and control. Also, lower scores of 
cardiovascular risk (by Framingham risk score and SCORE) were seen in the intervention 
group. Although the results of this study are not applicable to secondary prevention, the 
concept of personalizing patient education and information, sometimes with visual aids, is 
attractive. In patients with ischemic stroke, where all patients are high risk, visual aids could 
include a visual representation of carotid ultrasound or computed tomography (CT) 
angiography of the carotid arteries and thus proving the concept of atherosclerosis as a 
chronic disease process to the patient. Furthermore, in another study (primary and secondary 
prevention cohort) with positive results on statin adherence, patients received “risk factor 
passports” with graphical presentations of their own 10-year risk for adverse cardiovascular 
outcomes256.    
5.7.4 Focus on sex differences with increased patient and physician 
awareness 
Although not studied, to my knowledge, clinicians likely need to be made aware of the sex 
gap in statin treatment and the lack of evidence for treating men and women differentially. 
Speculatively, increased awareness may facilitate an increased statin prescribing and 
dispensing. An information intervention targeting both patients and physicians would be an 
interesting concept.  
5.7.5 Benefit of lower LDL targets in stroke may increase treatment 
Potentially, with the publication of the “Treat stroke to target”-trial showing benefit of a 
lower target LDL-level after TIA/stroke203, even more guideline emphasis will be put toward 
statin therapy thus improving treatment.  
5.7.6 Standardized care processes 
Sweden is in the process of launching a national initiative for personalized and connected 
care processes in stroke/TIA (“Personcentrerat och sammanhållet vårdförlopp Stroke och 
TIA”)266. Hopefully, this initiative will further improve the standards of care in ischemic 
stroke/TIA in Sweden, including reaching targets for medication use.  
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5.8 ANTICOAGULANT USE IN ATRIAL FIBRILLATION HAS INCREASED 
5.8.1 All patients with atrial fibrillation 
Anticoagulant use has increased from 2014-15 to 2016-17 in atrial fibrillation patients in 
Region Stockholm. The largest increase was seen in the group ≥85 years of age (71% to 
79%). These results are consistent with other contemporary studies on atrial fibrillation 
patients in Stockholm23,44.  
5.8.1.1 Sex differences in anticoagulant treatment remain but are small 
Sex differences in anticoagulant use in patients with atrial fibrillation in Region Stockholm 
remain but are no longer clinically relevant. Differences are small and have decreased over 
time which is consistent with another Region Stockholm study23. We aimed to study all 
patients with atrial fibrillation and a clear indication for treatment. The analysis is somewhat 
complicated by the divergence of local and international treatment guidelines during the time 
period of the study. If using international guidelines which state that treatment is indicated for 
men with CHA2DS2VASc ≥2 and women CHA2DS2VASc ≥3, then sex differences are even 
smaller than when all patients with CHA2DS2VASc ≥2 are included. Also, differences may 
no longer be statistically significant.  
5.8.2 Patients with ischemic stroke/TIA and atrial fibrillation 
In the cohort from 2006-2010 (study I), only 37% of patients with atrial fibrillation used 
anticoagulants 9-12 months after ischemic stroke/TIA. In patients with previous ischemic 
stroke/TIA 2011-15 and atrial fibrillation (study III), anticoagulant use had increased 
considerably, with 86% of patients using anticoagulants. This is consistent with national 
prescription data from the RiksStroke registry where a steady increase in patients with atrial 
fibrillation being discharged with anticoagulants has been seen for the past 10 years172. In 
2019, 80% of patients with atrial fibrillation were discharged with an anticoagulant2. The 
most common reason for withholding anticoagulants was that the physician adhered to 
instructions regarding contraindications, drug interactions, or caution (27%)2. The second 
most common reason was that the doctor wanted to start treatment after discharge (20% of 
patients not discharged with anticoagulant). Only 4% of non-treated patients declined 
treatment2.  
5.8.2.1 The sex gap in anticoagulant treatment after ischemic stroke/TIA has probably 
been closed in Stockholm 
Similarly to statins, the use of anticoagulants in patients with ischemic stroke/TIA and atrial 
fibrillation has increased for both sexes. The sex differences in the use of anticoagulants that 
were seen after ischemic stroke/TIA in study I (42% of men, 32% of women treated with 
anticoagulants), could no longer be seen in study III. Sex differences in study I were largely 
caused by women ≥80 being treated to a lesser degree than men, 22% vs 28%. These sex 
differences in study I were to some extent confounded by differences in income. However, in 
study III there were no longer any statistically significant differences in anticoagulant use 
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between sexes in any age group. In particular, it seems that medication use has evened out 
between sexes in the ≥80 age group. It should be noted that there are still sex differences in 
prescription of anticoagulants after ischemic stroke on the national level in the ≥80 age group 
(75% women, 80% men)2.  
5.8.3 Reasons for increased anticoagulant use in Stockholm 
5.8.3.1 Introduction of NOACs  
The structured introduction of NOACs in Region Stockholm56,267 meant that there was more 
focus on atrial fibrillation, both diagnosis and treatment, in general. During the period of 
NOAC introduction, the number of patients with an atrial fibrillation diagnosis increased 
substantially in Region Stockholm23,44,56. Also, marketing and educational activities from the 
pharmaceutical industry267, and increased media spotlight on atrial fibrillation23, may have 
been important contributors to increased anticoagulant use.  
5.8.3.2 Risk of falls should not be a reason to withhold anticoagulation 
Speculatively, studies downplaying the risk of falls as an important factor when choosing to 
anticoagulate patients with atrial fibrillation may have received increased attention during the 
structured introduction of NOACs. Risk of falling with a subsequent increase in the risk of 
bleeding is a common reason for withholding anticoagulant treatment268. However, the 
overall risk-benefit ratio for patients with atrial fibrillation at high risk of falls suggests that 
the risk of falls should not be a crucial factor in deciding whether or not to anticoagulate a 
patient269,270. One study estimated that a patient would have to fall approximately once every 
day (300 times/year) for the subdural hematoma risk from warfarin to overweigh the benefits 
of treatment270.  
5.8.3.3 Lower risk of bleeding with NOACs 
A major concern of anticoagulant treatment is the risk of bleeding, with an intracranial 
location the most worrying. Studies have shown that NOACs are associated with a lower risk 
of major bleeding and intracranial hemorrhage271,272 compared with warfarin. Thus, in 
patients judged to have an increased risk of bleeding, physicians could choose to treat with 
NOACs instead of warfarin which may have increased overall anticoagulant use.    
5.8.3.4 Aspirin discouraged in atrial fibrillation treatment 
National atrial fibrillation guidelines from the national board of health and welfare in 2013273, 
discouraged from using aspirin at all in patients with atrial fibrillation. With less focus on 
aspirin, more focus could be put towards treating with anticoagulants. However, it should be 
noted that local guidelines in Region Stockholm19 in 2012 still recommended aspirin as an 
option for patients with atrial fibrillation who could not be treated with anticoagulants. In 
2013, the guidelines emphasized that aspirin is considerably less effective than anticoagulants 
at preventing stroke, but still recommended aspirin as an option. This recommendation 
remained in 2015.  
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5.9 DIAGNOSIS RECORDING IS ASSOCIATED WITH GREATER MEDICATION 
USE 
Having a diagnosis recorded in primary care is associated with using more statins and 
antithrombotics in patients with previous ACS, ischemic stroke, and TIA. This association 
was also seen in study III for ischemic stroke and TIA. Nearly all recorded patients with atrial 
fibrillation and CHA2DS2VASc ≥2 in study IV used anticoagulants, but only about half of 
patients without a recorded diagnosis. An audit and feedback intervention did not have any 
clear effect on diagnosis recording. 
Diagnosis recording in TIA and ischemic stroke was similar in both study II and study III 
(after the intervention). It is debatable, and not yet known, which method is most suitable for 
defining diagnosis recording in primary care patients for these diagnoses. The method in 
study II has the advantage of standardizing recording to a certain duration of time (years 2 
and 3) after an event. Patients with multiple diagnoses were however excluded, limiting the 
utility in a real life primary care context. In this sense, the methodology in study III and IV 
has advantages in that it gives a real life representation of how all patients with a previous 
diagnosis are recorded. Also, some patients in study III and IV will have had their index 
diagnosis/event four or five years before the recording period, which may better reflect long 
term practices in diagnosis recording.    
Diagnosis recording in atrial fibrillation is considerably better than in patients with ischemic 
stroke, TIA, or ACS. The reasons for this are unclear. The higher diagnosis recording may be 
related to the fact that atrial fibrillation is, in general, a more commonly utilized diagnosis in 
primary care. It may be that atrial fibrillation is seen as an adequate diagnosis to input in the 
EMR than the other diagnoses, which may be more seen as acute events. Also, some patients 
with atrial fibrillation are only diagnosed and treated in primary care which may increase the 
likelihood of them receiving a primary care diagnosis179. Finally, treatment with 
anticoagulants requires extra attention from primary care which may increase the likelihood 
of an atrial fibrillation diagnosis.      
5.9.1 Association and not causation 
Having a diagnosis recorded in primary care is associated with greater medication use, but the 
causality is at present unclear. Physicians in primary care input their diagnosis in the 
electronic medical record after the patient encounter. The likelihood of a physician choosing 
to record a diagnosis is multifactorial and could be influenced by many factors - the doctor’s 
prior knowledge of the patient; the patient’s knowledge of their condition; patient 
comorbidities; the doctor’s knowledge of the condition in question; the prior existence (or 
not) of the diagnosis in available medical records; the doctor’s preferences and pattern of 
diagnosis selection; existence of a referral for the condition; financial reimbursement for 
recording274 the diagnosis; local traditions in diagnosis recording; and potentially other 
factors. At this point in time, we do not know the characteristics of the doctors, patients, and 
surrounding factors which lead to a diagnosis being or not being recorded.  
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5.9.2 Potential mechanisms 
Since non-recorded patients also use guideline recommended medications to a great extent, 
diagnosis recording is not a pre-requisite for treatment. Considering that it is difficult to know 
why certain doctors are more likely to diagnosis record, it is difficult to speculate in the 
mechanism of higher medication use in recorded patients. A potential mechanism could be 
that recording doctors have a greater knowledge of guidelines, or a greater interest in the 
condition in question. This would then, according to the theory, make them more likely to 
select a diagnosis and also to be adherent to existing diagnosis-relevant guidelines.    
5.9.3 Potential future areas of use 
Our study has shown that recording a diagnosis is associated with positive patient outcomes 
in the form of greater medication use. Medication use is, in itself, not a “hard outcome”, but 
is associated with benefit to patients in the form of decreased risk of future cardiovascular 
events31-37. Although diagnosis recording has already been implemented as a quality indicator 
for many diagnoses by Sweden’s “Quality in Primary Care”159, the concept of diagnosis 
recording has not yet been studied enough to draw conclusions regarding its utility. To 
validate diagnosis recording as a quality indicator it would have to be studied and compared 
with other outcomes of care. It would be interesting to study outcomes such as preventable 
hospitalizations, which are often suggested as useful quality indicators275, and mortality.   
The use of diagnosis recording in general quality improvement may have great potential. For 
internal quality improvement purposes, a higher degree of diagnosis recording would allow 
for more accurate audit of quality, since more patients would be included in the audit. Also, if 
computer decision support systems are to be implemented, for example to improve 
medication use, diagnosis recording may be important. The electronic medical record (EMR) 
would need to identify to which patients the CDS system is applicable. Currently, this can 
only be achieved by a diagnosis being recorded in the EMR, since the EMR is not connected 
to the national patient registry. Thus, while not being ready to implement as a quality 
indicator in itself, diagnosis recording may still be useful for other interventions, and general 
quality improvement purposes.  
5.10 AN AUDIT & FEEDBACK INTERVENTION DID NOT IMPROVE 
MEDICATION USE 
5.10.1 Audit & feedback did not improve medication use in patients with 
ischemic stroke/TIA or atrial fibrillation 
The audit & feedback intervention in study III and IV aimed to improve the use of secondary 
preventive medications in ischemic stroke/TIA patients (III) and anticoagulants in atrial 
fibrillation patients (IV). The intervention had either neutral (III) or small (IV) effects on 
medication use. Although there were small, statistically significant, differences between the 
intervention and control group in study IV after the intervention, the absolute differences 
were hardly clinically relevant. Control center patients increased their use of anticoagulants 
from 76 to 81% (5 percentage points), whereas intervention centers increased from 77 to 83% 
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(6 percentage points). Thus, I have chosen to discuss the reasons for the intervention not 
achieving better results.     
5.10.2 Potential reasons for our neutral/small results 
5.10.2.1 Predictors of effectiveness in audit and feedback interventions 
Ivers et al111 suggest the following factors that may predict the effectiveness of an audit and 
feedback intervention – (1) a low baseline performance; (2) a supervisor or colleague 
delivering the feedback; (3) >1 reminder; (4) feedback given in written and verbal form; (5) 
provides targets and an action plan.  
5.10.2.2 The intervention in relation to predictors of effectiveness 
We attempted to tailor our quality reports according to known success factors (2)-(5), but we 
do not know if the targeted doctors were able to appreciate these factors. The problem when 
assessing our intervention in relation to the predictors of effectiveness is that we cannot be 
sure if the intervention reached the intended targets, i.e. the primary care physicians. We 
targeted an intermediary, the primary care center directors, and depended on them 
disseminating the reports, and arranging internal meetings etc. This methodology has been 
used144 previously but then in combination with practice site visits and network meetings.  
Many audit and feedback interventions target physicians directly139,141,143,145. If the primary 
care center director embraces the intervention, it may have a greater effect. If they do not, 
there will not be an intervention at all in that center. In our follow up questionnaire, only 25% 
of centers gave some indication that they used the reports. Thus, it is likely that our 
intervention did not achieve the desired level of dissemination among primary care doctors 
and then the predictors of effectiveness may not matter.  
Regarding (1), which was out of our control, the baseline performance was relatively high in 
both study III and IV. In study III baseline performance before the intervention ranged from 
63% for statins; to 76% for antihypertensives; to 82% for both antiplatelets and 












Figure 9. Page 1 of a potential alternative format of quality reports, with more emphasis on medication 






5.10.2.3 The format of our reports 
The quality reports (appendix figure A1, de-identified version) contained a lot of written text 
and could, in retrospect, have been clearer regarding the current level of medication use at the 
centers. Also we could have related these medication levels to targets recommended by the 
NBHW17,18. We did provide current guidelines for how patients should be treated medically, 
but we did not provide an action plan as such on the reports. The action plan was only 
provided on one slide in the attached PowerPoint presentation. A different format for 
presenting data on medication use and diagnosis recording could have been chosen, such as 
that in figure 9 (for full four page quality report see appendix figure A2), which is a suggested 
alternative version of the quality reports. In this alternative report, more emphasis is put 
towards limiting text and graphically demonstrating medication use and diagnosis recording 
in the fictive primary care center “Fiktiv VC”. Also, an action plan is provided (page 3, see 
appendix figure A2).  
5.10.3 Could the intervention have been studied differently? 
5.10.3.1 Longer follow up 
Since our study outcome (medication use) was defined as two dispensations in an 18-month 
period, it is conceivable that any changes from an intervention would take time. The 
intervention was sent out in December 2015 to primary care center directors, but we do not 
know at what point in time there was an internal dissemination of our quality reports in the 
intervention centers. It is possible that the centers that actually used the reports, did so at 
some point in time during spring of 2016. If this was the case, then the intervention would 
only have had around 12 months to have a behavioral effect in doctors. It is possible that this 
time period is too short to discover potential effects of the intervention. We could have 
allowed more time to pass before analyzing medication use, for example analyzing 
medication use January 2017 – June 2018, and thus allowing a year for the intervention to 
have an effect. 
5.10.3.2 Interrupted time series analysis 
We could potentially have used a different study design utilizing interrupted time series 
analysis (ITS), which has become a popular tool for studying the effects of population based 
interventions276. It is being increasingly used in the study of medication use277. An ITS 
analysis study design is often selected in situations when randomization is not possible, like 
when an intervention targets an entire population278,279. For example, an Italian study from 
2011 examined the effect of a smoking ban in public places on hospitalizations for ACS 
using ITS analysis280. The principle of an ITS analysis is that it predicts the trend of an 
outcome over time in a population, given that the intervention had not taken place279. This is 
known as the “counterfactual”279. This counterfactual trend is then compared to the actual 
observed trend. If the counterfactual differs from the observed trend, the intervention has 
likely had an effect.  
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Although ITS analysis is usually applied when analyzing the total population effects of an 
intervention, it is also possible to use when intervention and control groups has been defined, 
such as in our study III and IV276,281. Thus, we could have performed an ITS analysis on our 
dataset. Since the outcome in our studies is defined as a number of dispensations in a 
relatively long time period (18 months), it can be expected to change gradually following our 
quality report intervention. We would have had to follow the patient cohort for several years 
following the intervention. Our original dataset only included data for 18 months following 
the intervention. Any future analysis of the intervention, by our group or others, should 
consider defining being treated as 2 dispensations per year and then performing an ITS 
analysis on the years before and after the intervention.  
An alternative study design for study III and IV could have been to send our intervention to 
all primary care centers in Region Stockholm. Then we could have used an ITS analysis in 
studying medication use of recommended medications after ischemic stroke/TIA and atrial 
fibrillation in the entire population of primary care patients. However, since this study design 
would not have included a control group, we would not have been able to determine the 
effects of competing interventions on the trends276. This would have been troublesome, since 
there was a lot of focus on atrial fibrillation in particular in Region Stockholm during the time 
of the study.    
5.10.3.3 Following one cohort through both dispensation periods 
We could potentially have chosen to follow stroke/TIA patients from index period A (2009-
2014) across both the dispensation periods A (before intervention) and B (after the 
intervention. The analyses before and after the intervention would then have been in the same 
patients. I have performed such an analysis for all medication classes, after excluding the 186 
patients (1.6%) who changed intervention status during the study (unpublished analysis). 
After performing multiple logistic regression analysis, adjusting for the same potential 
confounders as in study III, there was no effect of the intervention on any medication class. 
When studying only patients with atrial fibrillation diagnosis in 2009-14 in another 
unpublished analysis, results were similar to the analysis in the original publication (study 
IV). 
5.10.3.4 A specific intervention for only diagnosis recording? 
It would have been interesting to study an intervention focusing only on increasing diagnosis 
recording, without information on medication use. After such an intervention, outcomes such 
as medication use, recurrent ischemic stroke/TIA, and mortality could have been followed up. 
Currently we know that better diagnosis recording is associated with better medication use, 
but we do not know if increasing recording will increase medication use. For such a purpose 
it would be appropriate to not provide information on an intended outcome (medication use) 
in an intervention. A diagnosis recording intervention could be carried out in an entire region 
in Sweden, and studied with an ITS analysis.   
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5.10.4 Is audit & feedback useful in improving medication use after stroke? 
Audit & feedback is potentially a useful tool, but may not be effective in our setting with high 
baseline use. Also, it is important to determine the reasons for patients not using medications 
in the long term. Are patients not using the medications because the doctors are not 
prescribing, or are existing prescriptions not being filled in the pharmacy? Also, it would be 
important to know the reasons for non-prescribing. Future interventions, audit & feedback or 
other, would benefit from knowing where the problem lies (doctor or patient) and thus could 
be better tailored to address it.  
5.11 WHAT ARE REALISTIC TREATMENT GOALS AT A POPULATION LEVEL? 
The NBHW states that 80% of patients with atrial fibrillation and ischemic stroke should be 
treated with anticoagulant, 85% for TIA18. The selection of a somewhat higher target level for 
TIA is explained in the guidelines by the fact that TIA patients are expected to experience 
fewer side-effects than stroke patients. Regarding statins, 80% of patients with ischemic 
stroke should be treated with statins, with the same recommendation for TIA. The rationale 
from the NBHW for the target not being 100% is that side-effects will make such a goal 
unattainable and there must be some room to operate. However, the rationale for selecting 
proportions such as 80% or 85% are not explicitly explained18. In likelihood these 
proportions are arbitrarily chosen from clinical experience. I believe that these levels are 
achievable and reasonable, but we must never forget the importance of patient involvement in 
the decision making in the treatment of chronic conditions282,283.   
5.12 WHERE ARE RESOURCES MOST WELL USED IN ATRIAL FIBRILLATION 
MANAGEMENT? 
In the included primary care centers in Region Stockholm, the use of anticoagulants in 
patients with atrial fibrillation was 82% in 2016-17. The treatment proportion is currently 
≥75% in all age groups (when studying men with CHA2DS2VASc ≥2 and women with 
CHA2DS2VASc ≥3). This means that research interventions with the goal of improving 
medication use further, in likelihood would be resource consuming relative to the small 
expected increases in medication use. The recently published ESC atrial fibrillation 
guidelines emphasize the importance of a holistic approach to the management of atrial 
fibrillation, in which strategies to promote medication adherence is only one of several 
components21. In our setting, with high use of anticoagulants, the approach of shifting focus 
from medication use improvement to managing cardiovascular comorbidity, lifestyle factors, 
psychosocial factors, and patient self-management seems reasonable. However, in settings 
where use of anticoagulants is still low, of course more resources are warranted towards 
purely improving medication use. Worthy of note among planned interventional trials is 
“STEER-AF”284. Patients with atrial fibrillation will be included from approximately 70 
centers in six European countries. The centers will be randomized to a comprehensive 
educational intervention targeting healthcare professionals, or to no intervention. Among the 
outcomes being studied are guideline adherence among healthcare professionals; guideline 
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adherence for rhythm control and stroke prevention; proportion of patients with appropriate 












6 MAIN STRENGHTS AND LIMITATIONS 
6.1 STRENGHTS 
All our studies have used registries/databases with high validity, thus ensuring a high quality 
of data. The registries/databases have allowed for research on unselected, sizeable cohorts in 
a region of approximately 2 million inhabitants with a uniform healthcare system. Linkage of 
data between registries in Sweden is advantageous and enables the combining and use of 
different kinds of data. Including approximately 200 primary care centers in an intervention 
is another strength specific to study III and IV. The availability of data from both national 
registries and primary care in studies II-IV enables analyses that are currently not possible 
on the national level.  
6.2 LIMITATIONS 
Many of the limitations of the studies in this thesis have already been mentioned in the 
methodological considerations section (section 3) and this section should be examined by the 
reader for a more complete picture.  
6.2.1 Generalizability 
Our studies were conducted in Region Stockholm with the advantages elaborated on in the 
“strengths” section. While there are advantages of studying a defined region, it must be 
recognized that our results may not be generalizable to other regions abroad, or in Sweden. 
Medication use and diagnosing recording patterns in ischemic stroke/TIA/atrial fibrillation 
likely have regional variations within and outside Sweden. Also, healthcare is organized 
differently in different areas of Sweden and internationally. For example, the fact that our 
intervention in studies III and IV was neutral is likely generalizable to other urban, high-
income country settings with high baseline medication use. It cannot be excluded that similar 
interventions would have an effect on medication use in other settings. Diagnosis recording 
may be influenced by regional financial incentives and healthcare organization, thus limiting 
the generalizability of the results in study II.  
6.2.2 Not all patients in Region Stockholm were included in the unpublished 
analyses    
The additional unpublished analyses in this thesis have been performed using the same 
inclusion and exclusion criteria as in the original publications. For study III and IV, this 
meant excluding patients that are not listed at any primary care center, patients living in 
nursing homes; deceased patients; patients <18 years of age, and patients in the excluded 
primary care centers.  If I had only excluded deceased patients or patients not living in 
Region Stockholm, there would have been 15 550 patients (instead of 12 766) in the analysis 
in study III, and 37 401 patients with CHA2DS2VASc score ≥2 (instead of 31 477) in study 
IV. Thus, the use of preventive medication in all patients in Region Stockholm may differ 
somewhat to the unpublished analyses of study III and IV presented in this thesis.   
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6.2.3 Definition of medication use 
6.2.3.1 Medication dispensation does not equal actual intake of medicine.  
While medication use in all the studies in this thesis has been defined as medication 
dispensations, it should be appreciated that simply picking up a medication in the pharmacy 
does not equal actual intake of medication. However, dispensation is likely the best option 
when conducting large studies on medication use.  
6.2.3.2 Defining medication use as two dispensations 
Defining medication use as two medication dispensations is somewhat arbitrary. For this 
reason the sensitivity analyses that we have carried out are important, when medication use is 
defined as different numbers of dispensation. Possibly, three or even four dispensations could 
have been used as the baseline definition of medication use during an 18-month period. With 
three or four dispensations as a starting point, sensitivity analysis of more and less 
dispensations could have been performed. However, choosing to have another baseline for 
number of dispensations defining on-treatment would have been just as random as defining 
treatment as two dispensations. Choosing multiple dispensations may be better than just a 
single dispensation when defining treatment, since one dispensation could mean that a patient 
has quit straight away after starting. Multiple dispensations implies an intent to continue 
treatment on the patient’s part.       
6.2.4 Where does the problem lie – prescriber or patient? No prescription 
data 
The studies in this thesis have all used medication dispensation as an end-point. Our study 
design cannot establish how much of non-medication use is related to patient factors – i.e. not 
picking up existing prescriptions, taking medication irregularly – and how much is related to 
physician factors – i.e. not prescribing, failing to motivate patients, not addressing side-
effects adequately etc. It is possible to know what medications patients are prescribed through 
RiksStroke, but information is only available at the index event. Being able to use 
prescription data from primary care would be very valuable in future studies of long term, 
chronic medication use. However, this type of prescription data is not currently available in 
Sweden.       
6.2.5 Residual confounding in database research 
We have attempted to use the available registries as thoroughly as possible with regards to 
obtaining, and adjusting for, confounding. However, in research, and registry research in 
particular, there will often be residual confounding – i.e. the existence of confounders which 
have not been adjusted for.   
When studying the association of an exposure and an outcome it is important to appreciate 
that the association may be caused by a confounder. A confounder is a factor which is 
associated with both the exposure and the outcome variable. There are several ways to handle 
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confounding. One way is to adjust for confounding factors in the analysis phase of a study. In 
order to adjust for a confounder, we must have data on that confounder. In registry research, 
we are constrained by the fact that we only have the data which the registry provides us with. 
Therefore, there may be numerous confounders which we cannot adjust for, simply because 
we do not have data on them. The NPR and VAL do not have data on lifestyle factors such as 
smoking, physical activity, alcohol use, occupation etc. In study I we could adjust for 
socioeconomic factors, which were not available in studies II-IV. In study III-IV we had data 
on comorbidity and primary care center characteristics which were not available in the data 
set in study I. It should be noted that we could have acquired, and adjusted for, more data on 
comorbidities in study I. Data was available in VAL, but was not included in our data set. So 
sometimes the variable of interest does not exist in the registry of interest (e.g. smoking), and 
sometimes it does exist but has not been extracted and used in the data set.  
6.2.6 Multiple analyses and type I errors 
When working with a large data sets and carrying out numerous analyses, it should be 
appreciated that the risk of making a type I error increases. A type I error is a situation where 
the null hypothesis is actually true, but is falsely rejected, i.e. the findings are reported as 
significant when they are not. This has likely not been a problem in the analyses in the studies 
included in this thesis.   
6.2.7 Insufficient analysis of the intervention in study III and IV 
Our audit & feedback intervention in primary care showed neutral results. We do not know if 
the cause of these neutral results was lack of dissemination/use of the intervention, or the 
content in itself. We did send out a questionnaire to all primary care center directors with 
questions about the intervention, but this was done in the autumn of 2018. The response 
frequency was low (12%). Some centers had changed directors since the intervention and had 
not heard of it. A questionnaire in late 2016 would have been more appropriate. This would 
likely have resulted in a higher response frequency. Furthermore, it would have been 
interesting to perform more in depth, qualitative, interviews with a sample of the primary care 
center directors. This may have allowed for a better understanding of their reasons for using, 




7 CONCLUSIONS   
 
 Use of recommended preventive medications in Region Stockholm has increased over 
time in both patients with prior ischemic stroke/TIA and patients with atrial 
fibrillation. 
 Women in Region Stockholm use less statins than men after ischemic stroke/TIA. 
The sex gap in statin use after ischemic stroke/TIA has persisted over time and it is 
important that measures are taken to improve treatment in women.  
 High income was associated with being dispensed more statins, anticoagulants, and 
antiplatelets 9-12 months after ischemic stroke/TIA in Region Stockholm.  
 Having a diagnosis recorded in primary care was associated with using more 
secondary preventive medication after ischemic stroke, hemorrhagic stroke, TIA, and 
acute coronary syndrome in Region Stockholm. 
 An audit & feedback intervention did not improve the use of preventive stroke 
medications in primary care in Region Stockholm. 
 Diagnosis recording of TIA and atrial fibrillation was slightly better in intervention 
centers than control centers, after (but not before) an audit & feedback intervention in 
Region Stockholm. However, absolute differences between groups were small.   
 An audit & feedback intervention did not have any effect on diagnosis recording in 




8 FUTURE PERSPECTIVES 
8.1 INCREASING STATIN USE IN WOMEN 
Statins appear to be the preventive medication class which requires most attention, relative to 
the other classes where use is better. Improving statin use in women would achieve both 
increased statin use in the entire population, but would also target sex inequalities. Thus, a 
study with the intention of increasing the use of statins in women after ischemic stroke/TIA 
should be a top priority for future research. It could be called the Bringing Equality to Statin 
Treatment study or the BEST-study. This study has not yet been planned so the design of an 
intervention has not been defined. Speculatively, the intervention would likely be carried out 
in all of Region Stockholm, with another comparable Swedish region as control. Potential 
contents of an intervention to increase statin use have been previously discussed in this thesis. 
Additionally, hospitals and primary care centers could be provided with sex specific audit & 
feedback statin prescription and dispensation data on their stroke/TIA patients.  
8.2 A STUDY WITH BOTH PRESCRIPTION AND DISPENSATION DATA 
It would be interesting to conduct a study on the long term medication use in patients with 
ischemic stroke/TIA using RiksStroke data on prescription, and dispensation data. A time 
period of five years after an initial event could be used. In this study we could document 
prescription and primary non-adherence as well as long term persistence and adherence. We 
could also use “dispensations in a time period” to define treatment after five years and see 
how this relates to adherence and persistence. Interesting questions to answer would be for 
example – do patients who have been defined as non-persistent in previous, shorter, studies 
actually start treatment again?  
8.3 BETTER UNDERSTANDING OF DIAGNOSIS RECORDING 
The underlying processes/mechanisms which determine if a primary care physician chooses 
to record or not record a diagnosis are poorly understood. Qualitative studies with primary 
care physicians are needed, as well as comparisons of diagnosis recording habits across 
different healthcare regions in Sweden, with different reimbursement systems for recording.  
8.4 REPEATING STUDIES ON SOCIOECONOMY AND MEDICATION USE 
As has been mentioned previously in this thesis, the associations between socioeconomic 
factors and medication use may have changed over time. Thus, repeating previous studies 




9 SAMMANFATTNING PÅ SVENSKA  
Bakgrund: Mediciner kan förebygga insjuknande i stroke men används inte alltid i tillräcklig 
utsträckning av patienter. Det övergripande syftet med denna avhandling var att studera 
medicinanvändning hos patienter med tidigare ischemisk stroke eller transitorisk ischemisk 
attack (TIA), och hos alla patienter med förmaksflimmer. Socioekonomiska- och 
demografiska faktorer som kön, inkomst och utbildning har associerats med skillnader i 
medicinanvändning efter stroke. Om man kan få bättre insikt kring dessa associationer kan 
det förbättra förståelsen av varför medicinanvändningen hos patienter är otillräcklig. Patienter 
med tidigare stroke följs långsiktigt inom primärvården i Sverige. Därför är det rimligt att 
interventioner med syfte att förbättra medicinanvändning fokuserar på vårdcentraler. Efter 
varje patientbesök hos läkare på vårdcentral behöver läkaren registrera en diagnos för 
besöket, som förs in i den elektroniska patientjournalen. Denna diagnosregistrering har 
föreslagits som en möjlig kvalitetsindikator för god vård inom primärvården. Dock är 
diagnosregistrering fortfarande otillräckligt studerat för att veta om det skulle vara användbart 
som en sådan indikator. Associationen mellan läkemedelsanvändning och diagnosregistrering 
har inte studerats. ”Audit & feedback” (ungefär ”Granska & återkoppla”) är en vanlig och 
välstuderad metod för att åstadkomma beteendeförändringar hos sjukvårdspersonal. Om en 
intervention gentemot primärvårdsläkare skulle lyckas öka läkarnas förskrivning av 
förebyggande läkemedel och motiverande av patienter med stroke/förmaksflimmer att ta 
dessa, skulle medicinanvändningen potentiellt kunna öka. 
Metoder: Alla studier i denna avhandling är registerbaserade och har inkluderat patienter 
≥18 års ålder i Region Stockholm. Utfallsmåttet i alla studier har varit medicinanvändning. 
Från det svenska Läkemedelsregistret har vi kunnat använda uthämtade läkemedel på apotek 
som ett mått på medicinanvändning. I studie I länkades data från VAL (se nedan), 
Läkemedelsregistret och Statistiska Centralbyrån. I studier II-IV användes databasen för 
uppföljning och analys av sjukvårdskonsumtion och produktion i Region Stockholm – VAL 
databasen. Data i VAL är identisk med data i Patientregistret och sedan 2010 också 
Läkemedelsregistret. I studie I undersökte vi associationen mellan sociodemografiska 
faktorer och medicinanvändning 9-12 månader efter ischemisk stroke/TIA. I studie II 
undersökte vi associationen mellan diagnosregistrering i primärvård och medicinanvändning 
hos patienter med tidigare stroke/TIA och akut koronart syndrom. Studie III och IV testade 
om en ”audit & feedback” intervention riktad till primärvårdsläkare kunde förbättra 
medicinanvändning hos patienter med tidigare ischemisk stroke/TIA (III) eller 
förmaksflimmer (IV).   
Resultat/slutsatser: Strokeförebyggande medicinanvändning av alla rekommenderade 
läkemedelsklasser har ökat över tid hos patienter med tidigare ischemisk stroke/TIA och hos 
patienter med förmaksflimmer. Statiner är den läkemedelsklass som används minst efter 
ischemisk stroke/TIA, och kvinnor använder mindre statiner i alla åldersklasser. Framtida 
interventioner bör sträva ha som mål att jämna ut könsskillnaderna i statinanvändning. Högre 
inkomst var associerat med ökad användning av statiner, antikoagulantia och 
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trombocythämmare 9-12 månader efter ischemisk stroke/TIA. Diagnosregistrering var 
associerat med ökad läkemedelsanvändning hos patienter med stroke/TIA, akut koronart 
syndrom och förmaksflimmer. En ”audit & feedback”-intervention lyckades inte förbättra 
läkemedelsanvändningen hos primärvårdspatienter med tidigare ischemisk stroke/TIA eller 
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